≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Malignant neoplasm of ureter, including Hilmo

Endpoint Browser PheWeb

C3_URETER_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C66
  • Hospital discharge: ICD-9 — 189[2-3]
  • Hospital discharge: ICD-8 — 1892
  • Cause of death: ICD-10 — C66
  • Cause of death: ICD-9 — 189[2-3]
  • Cause of death: ICD-8 — 1892
  • Cancer registry: Topography ICD-O-3 — C66
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

315

4. Check minimum number of events

None

315

5. Include endpoints

None

315

6. Filter based on genotype QC (FinnGen only)

300

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 300 82 218
Unadjusted period prevalence (%) 0.08 0.03 0.10
Median age at first event (years) 73.40 73.44 73.38

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
315
Matched controls
3150
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C66
ICD-10 Finland
Malignant neoplasm of ureter
+∞
307.7
292
*
UKC02
NOMESCO Finland
Cystoscopy
51.7
232.3
276
379
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
196.0
167
*
KCD02
NOMESCO Finland
Transurethral resection of bladder
561.5
163.4
149
5
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
57.8
161.1
94
23
R31
ICD-10 Finland
Unspecified haematuria
18.3
159.0
196
260
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
69.2
153.9
86
17
UKB02
NOMESCO Finland
Retrograde ureteroscopy
271.2
144.4
138
9
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
60.3
110.7
63
13
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
308.7
108.1
104
5
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
1390.6
105.7
97
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
32.4
104.8
71
28
JN4AD
NOMESCO Finland
Body CT examination
14.4
104.5
114
119
H02AB02
ATC
dexamethasone; systemic
48.0
103.5
62
16
8120/3-C66.9
ICD-O-3
Transitional cell carcinoma, NOS, of ureter
+∞
99.4
90
*
D41.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Ureter
+∞
99.4
90
*
130
Kela drug reimbursment
Malignant tumour
+∞
95.8
87
*
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
41.6
93.4
58
17
KAC20
NOMESCO Finland
Nephroureterectomy
+∞
90.0
82
*
C65
ICD-10 Finland
Malignant neoplasm of renal pelvis
+∞
85.4
78
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
17.6
83.9
75
55
KH1AD
NOMESCO Finland
CT of urinary organs
18.0
82.9
73
52
KAC21
NOMESCO Finland
Percutaneous endoscopic nephroureterectomy
+∞
76.2
70
*
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
+∞
71.6
66
*
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
185.7
71.3
72
5
JN4BD
NOMESCO Finland
Extensive body CT
12.5
68.9
76
78
C61
ICD-10 Finland
Malignant neoplasm of prostate
811.9
68.7
65
*
Z51.5
ICD-10 Finland
Palliative care
11.3
64.6
77
88
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
62.6
58
*
UKA02
NOMESCO Finland
Retrograde ureteronephroscopy
370.6
61.7
60
*
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
150.6
59.2
61
5
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
125.6
58.2
61
6
A04AA01
ATC
ondansetron; systemic, rectal
20.5
57.9
46
26
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
8.9
57.4
84
124
B01AB10
ATC
tinzaparin; parenteral
7.9
53.9
89
150
JN4CD
NOMESCO Finland
Very extensive body CT
22.8
52.9
40
20
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
52.6
49
*
XX3DW
NOMESCO Finland
Time consuming IT work
11.6
51.7
58
60
TPH07
NOMESCO Finland
Cathetrisation of artery
6.5
48.6
100
210
WX408
NOMESCO Finland
General anesthesy, balanced
5.4
48.0
142
413
A03FA01
ATC
metoclopramide; systemic, rectal
6.6
48.0
96
196
JN3AD
NOMESCO Finland
Abdominal CT examination
6.6
47.7
95
193
KBD00
NOMESCO Finland
Partial excision of ureter
+∞
47.1
44
*
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
68.8
46.0
52
9
KA1AE
NOMESCO Finland
Kidney ultrasound examination
15.5
45.9
42
31
KBJ10
NOMESCO Finland
Cutaneous ureteroenterostomy
+∞
42.7
40
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
42.7
40
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
12.0
41.1
44
42
KBH20
NOMESCO Finland
Replantation of ureter
413.7
37.9
37
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.9
37.8
113
323
J01MA02
ATC
ciprofloxacin; systemic
4.4
35.8
202
916
WX402
NOMESCO Finland
General anaesthesia
4.8
35.6
108
311
ZX136
NOMESCO Finland
Intravesicalis
202.4
35.5
36
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
35.1
33
*
U06
ICPC
Haematuria
10.3
33.7
40
44
TKC20
NOMESCO Finland
Catheterisation of bladder
6.0
33.7
69
141
WZC00
NOMESCO Finland
Treatment plan or consultation
4.2
33.4
138
497
8130/2-C66.9
ICD-O-3
Papillary urothelial carcinoma, non-invasive of ureter
+∞
32.9
31
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
32.9
31
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
358.3
32.5
32
*
KBB00
NOMESCO Finland
Biopsy of ureter
+∞
31.8
30
*
WC305
NOMESCO Finland
Simple therapy of local tumor recidive with biomodifiers
+∞
31.8
30
*
8130/2-C67.9
ICD-O-3
Papillary urothelial carcinoma, non-invasive of bladder, NOS
+∞
31.8
30
*
WZC30
NOMESCO Finland
Teaching
4.9
31.1
85
223
KA3EB
NOMESCO Finland
Antegrade pyelography
+∞
30.7
29
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.9
30.6
83
216
KCC10
NOMESCO Finland
Cystoprostatectomy
+∞
29.6
28
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
4.5
29.2
88
248
KC1GB
NOMESCO Finland
Cystography with X-ray
165.2
29.2
30
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
4.2
28.7
99
309
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
+∞
28.6
27
*
116
Kela drug reimbursment
Prostate cancer
+∞
27.5
26
*
N02AA05
ATC
oxycodone; systemic
4.0
27.5
101
329
B01AB05
ATC
enoxaparin; parenteral
3.6
27.2
150
639
KH1BD
NOMESCO Finland
Extensive urinary tract CT examination
57.1
26.7
31
6
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
9.1
25.7
33
40
8120/3-C65.9
ICD-O-3
Transitional cell carcinoma, NOS, of renal pelvis
+∞
24.3
23
*
C67.0
ICD-10 Finland
Malignant neoplasm: Trigone of bladder
+∞
24.3
23
*
J01EA01
ATC
trimethoprim; systemic
3.5
23.5
109
410
XKD00
NOMESCO Finland
Uroflowmetry
3.5
23.4
109
411
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
23.2
22
*
ZXE20
NOMESCO Finland
More than three and less than five hours
4.0
22.9
78
238
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.6
22.3
96
343
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
+∞
22.1
21
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
22.1
21
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
22.1
21
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
21.1
20
*
U76
ICPC
Malignant neoplasm of bladder
+∞
21.1
20
*
L02AE02
ATC
leuprorelin; implant, parenteral
+∞
21.1
20
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
82.6
21.0
23
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
20.0
19
*
WX320
NOMESCO Finland
Spinalanesthesy
3.1
19.9
124
549
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
112.1
19.8
21
*
WF002
NOMESCO Finland
Radical radiotherapy
112.1
19.8
21
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.2
19.8
107
436
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
9.0
19.5
25
30
D41.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Renal pelvis
74.6
18.9
21
*
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
+∞
18.9
18
*
KBV10
NOMESCO Finland
Removal of stent from ureter
41.1
18.8
23
6
J01MA12
ATC
levofloxacin; systemic
3.2
18.4
95
375
N30.0
ICD-10 Finland
Acute cystitis
3.6
18.2
73
246
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
56.0
18.2
21
*
KCC20
NOMESCO Finland
Cystoprostatourethrectomy
+∞
17.9
17
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
17.9
17
*
R82.8
ICD-10 Finland
Abnormal findings on cytological and histological examination of urine
+∞
17.9
17
*
ZXE00
NOMESCO Finland
One hour or less
2.8
17.4
151
787
KBV00
NOMESCO Finland
Insertion of stent into ureter
53.1
17.2
20
*
KBD22
NOMESCO Finland
Retrograde ureteroscopic destruction of tumour of ureter
+∞
16.8
16
*
ZXC20
NOMESCO Finland
Use of chemical agents
16.5
16.5
26
17
ZXE30
NOMESCO Finland
More than five and less than seven hours
6.4
16.3
28
47
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
15.8
15
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
15.8
15
*
A79
ICPC
Malignancy NOS
+∞
15.8
15
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
15.8
15
*
KA3GB
NOMESCO Finland
Retrograde pyelography
168.0
15.6
16
*
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
168.0
15.6
16
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.9
15.6
50
144
ZXE10
NOMESCO Finland
More than one and less than three hours
2.6
15.5
140
734
ZX120
NOMESCO Finland
Intravenous
4.5
15.5
41
102
KH1AA
NOMESCO Finland
Urinary tract X-ray examination without contrast
17.2
15.5
24
15
Z3231
NOMESCO Finland
Registered nurse
2.8
15.5
111
519
TKW99
NOMESCO Finland
Other minor surgical procedure in urology
21.4
15.3
22
11
ZX090
NOMESCO Finland
Other technic of radiotherapy
59.7
14.9
17
*
KCB00
NOMESCO Finland
Biopsy of bladder
84.1
14.7
16
*
115
Kela drug reimbursment
Breast cancer
+∞
14.7
14
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
14.7
195
1219
8120/2-C67.9
ICD-O-3
Urothelial carcinoma in situ of bladder, NOS
157.0
14.6
15
*
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.7
14.6
52
161
KCW96
NOMESCO Finland
Other operations on bladder
44.7
14.2
17
*
K43.9
ICD-10 Finland
Other and unspecified ventral hernia without obstruction or gangrene
5.9
14.1
26
47
Y83.9
ICD-10 Finland
Surgical procedure, unspecified as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
6.9
13.8
22
34
TJF80
NOMESCO Finland
Ostomy education
78.6
13.7
15
*
N13.1
ICD-10 Finland
Hydronephrosis with ureteral stricture, not elsewhere classified
+∞
13.6
13
*
L02BB03
ATC
bicalutamide; oral
+∞
13.6
13
*
Y77
ICPC
Malignant neoplasm prostate
146.0
13.6
14
*
L03AA13
ATC
pegfilgrastim; parenteral
146.0
13.6
14
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
10.0
12.7
25
27
GD1AD
NOMESCO Finland
Thorax CT examination
4.1
12.7
37
99
L03AA02
ATC
filgrastim; parenteral
+∞
12.6
12
*
C67
ICD-10 Finland
Malignant neoplasm of bladder
+∞
12.6
12
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
12.6
12
*
L02BG04
ATC
letrozole; oral
+∞
12.6
12
*
C68.0
ICD-10 Finland
Malignant neoplasm: Urethra
+∞
12.6
12
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
12.6
12
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
12.6
12
*
A04AD12
ATC
aprepitant; systemic
+∞
12.6
12
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
12.6
12
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
135.2
12.5
13
*
KH1DD
NOMESCO Finland
CT urography of urinary organs
135.2
12.5
13
*
R4110
NOMESCO Finland
Physiotherapy
2.5
11.8
103
519
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
11.5
11
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
11.5
11
*
8120/3-C68.9
ICD-O-3
Transitional cell carcinoma, NOS, of urinary system, NOS
+∞
11.5
11
*
KH1YT
NOMESCO Finland
Percutaneous implantation of endoprothesis with radiological guidance
124.4
11.5
12
*
ZXC15
NOMESCO Finland
Use of photodynamic technique
17.9
11.3
17
10
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
4.0
10.6
31
83
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
113.7
10.5
11
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
113.7
10.5
11
*
UKD02
NOMESCO Finland
Urethroscopy
33.8
10.4
13
*
KCW02
NOMESCO Finland
Lavation of bladder for coagulated blood
13.7
10.3
17
13
ZXD10
NOMESCO Finland
Scheduled procedure
2.2
10.0
135
809
WX882
NOMESCO Finland
High dependency care
5.2
9.9
21
43
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
7.8
9.9
22
30
B02AA02
ATC
tranexamic acid; systemic
3.2
9.7
40
135
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
5.0
9.7
21
44
Z3226
NOMESCO Finland
Physiotherapist
2.5
9.6
69
315
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.0
9.6
46
170
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
8.0
9.6
21
28
N02AX02
ATC
tramadol; systemic, rectal
2.1
9.6
154
983
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
4.9
9.4
21
45
C67.4
ICD-10 Finland
Malignant neoplasm: Posterior wall of bladder
+∞
9.4
9
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
9.4
9
*
C68.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of urinary organs
+∞
9.4
9
*
1888X
ICD-9 Finland
Malignant neoplasm of bladder, Other specified sites of bladder
+∞
9.4
9
*
KCD30
NOMESCO Finland
Destruction of tumour of bladder
+∞
9.4
9
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
9.4
9
*
KBC00
NOMESCO Finland
Ureterectomy
+∞
9.4
9
*
Z2221
NOMESCO Finland
Medical doctor
2.3
9.4
90
467
U14
ICPC
Kidney symptom/complaint
8.1
9.3
20
26
R50.9
ICD-10 Finland
Fever, unspecified
2.6
9.2
59
254
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
4.4
9.1
23
55
N18.8
ICD-10 Finland
Other chronic renal failure
4.5
8.5
21
49
JFB00
NOMESCO Finland
Partial resection of small intestine
20.7
8.5
12
6
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
4.0
8.5
25
67
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
92.4
8.5
9
*
KC1GD
NOMESCO Finland
CT cystography of bladder
92.4
8.5
9
*
KED22
NOMESCO Finland
Transurethral resection of prostate
2.8
8.4
45
176
HAC20
NOMESCO Finland
Total mastectomy
+∞
8.4
8
*
U77
ICPC
Malignant neopl urinary tract other
+∞
8.4
8
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
+∞
8.4
8
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
8.4
8
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
8.4
8
*
WX224
NOMESCO Finland
Blockade of obturius nerve
+∞
8.4
8
*
L01BC06
ATC
capecitabine; oral
+∞
8.4
8
*
C03CA01
ATC
furosemide; systemic
2.0
8.2
151
996
N20.1
ICD-10 Finland
Calculus of ureter
4.1
8.1
23
60
WX702
NOMESCO Finland
Supraglottic ventilation device
4.1
8.1
23
60
NK6AN
NOMESCO Finland
Total body bone isotope imaging
34.3
8.1
10
*
KA1FN
NOMESCO Finland
Isotope renography
22.7
8.1
11
5
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
3.9
8.1
24
65
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.2
7.9
32
107
JFB30
NOMESCO Finland
Right hemicolectomy
25.7
7.6
10
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.5
7.4
53
240
WX704
NOMESCO Finland
Intubation
3.1
7.4
31
106
SPAT1262
SPAT
Handing over of treatment supplies
2.2
7.3
75
396
UKB12
NOMESCO Finland
Retrograde endoscopy of cutaneous ureteroenterostomy
+∞
7.3
7
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
7.3
7
*
C67.1
ICD-10 Finland
Malignant neoplasm: Dome of bladder
+∞
7.3
7
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
7.3
7
*
D09.0
ICD-10 Finland
Carcinoma in situ: Bladder
+∞
7.3
7
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
7.3
7
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
7.3
7
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
7.3
7
*
C44.32
ICD-10 Finland
Spinocellular carcinoma of the skin on another or unspecified part of the face
+∞
7.3
7
*
Z93.6
ICD-10 Finland
Other artificial openings of urinary tract status
+∞
7.3
7
*
UKC12
NOMESCO Finland
Retrograde endoscopy of cutaneous cystoenterostomy
+∞
7.3
7
*
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
+∞
7.3
7
*
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
4.1
7.3
20
51
WX110
NOMESCO Finland
Infiltration anesthesia
1.9
7.3
202
1509
S18
ICPC
Laceration/cut
1.9
7.2
164
1146
U70
ICPC
Pyelonephritis/pyelitis
8.2
7.2
15
19
N13.9
ICD-10 Finland
Obstructive and reflux uropathy, unspecified
30.8
7.2
9
*
U29
ICPC
Urinary symptom/complaint other
4.0
7.1
20
52
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
4.6
7.0
17
39
ZXA05
NOMESCO Finland
Left side
2.0
7.0
94
550
N02BE01
ATC
paracetamol; systemic, rectal
2.6
6.9
279
2367
R93.4
ICD-10 Finland
Abnormal findings on diagnostic imaging of urinary organs
11.3
6.9
12
11
A06AH03
ATC
naloxegol; oral
17.2
6.8
10
6
B03XA02
ATC
darbepoetin alfa; parenteral
7.4
6.8
15
21
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.3
6.8
58
284
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.2
6.7
64
327
KDE20
NOMESCO Finland
Removal of foreign body from urethra
23.1
6.7
9
*
ZXE40
NOMESCO Finland
More than seven and less than nine hours
8.1
6.7
14
18
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
12.6
6.6
11
9
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
9.0
6.6
13
15
R33
ICD-10 Finland
Retention of urine
2.3
6.6
52
246
WW500
NOMESCO Finland
Blood transfusion
5.9
6.5
17
30
HAB40
NOMESCO Finland
Wedge excision of mammary gland
71.2
6.4
7
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.4
6.4
46
209
TKE00
NOMESCO Finland
Needle biopsy of prostate
3.8
6.3
19
52
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
+∞
6.3
6
*
8070/3-C44.9
ICD-O-3
Squamous cell carcinoma, NOS, of skin, NOS
+∞
6.3
6
*
8120/2-C66.9
ICD-O-3
Urothelial carcinoma in situ of ureter
+∞
6.3
6
*
7323
FHL
Electrosection of TU bladder wall change
+∞
6.3
6
*
KBJ60
NOMESCO Finland
Anastomosis of ureter to urethra with interposition of ileum
+∞
6.3
6
*
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
+∞
6.3
6
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
6.3
6
*
D30.2
ICD-10 Finland
Benign neoplasm: Ureter
+∞
6.3
6
*
KAC10
NOMESCO Finland
Total nephrectomy with capsule
+∞
6.3
6
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
KBD20
NOMESCO Finland
Destruction of tumour of ureter
+∞
6.3
6
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
6.3
6
*
KBJ80
NOMESCO Finland
Operation for malfunction of urinary diversion
+∞
6.3
6
*
C67.3
ICD-10 Finland
Malignant neoplasm: Anterior wall of bladder
+∞
6.3
6
*
KH1RT
NOMESCO Finland
Urinary tract dilatatation with radiological guidance
+∞
6.3
6
*
N12
ICD-10 Finland
Tubulo-interstitial nephritis, not specified as acute or chronic
6.5
6.2
15
24
KDV12
NOMESCO Finland
Urethroscopic internal urethrotomy
12.9
6.1
10
8
J01DB01
ATC
cefalexin; oral
2.0
6.1
245
2006
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
10.3
6.1
11
11
G04BD12
ATC
mirabegron; oral
2.2
6.0
56
283

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Urology
34 [38004474]
1.8e+00
3.9e+00
5.5e+00
—
5.3e+00
5.2e+00
4.2e+00
cases:38.34%
controls:9.47%
cases:66.77%
controls:4.00%
cases:47.28%
controls:0.38%
—
—
cases:53.23%
controls:0.55%
cases:87.76%
controls:3.79%
cases:87.98%
controls:10.13%
120
296
193
2831
209
125
104
3002
148
12
165
3115
—
165
17
145
3101
251
114
35
2890
161
239
22
2121
Cytology report of Urine Cyto stain
47525-1 [3049717]
2.8e+00
4.6e+00
—
1.0e+50
—
5.6e+00
4.5e+00
cases:16.29%
controls:1.12%
cases:31.95%
controls:0.45%
—
—
cases:3.19%
controls:0.00%
—
—
cases:32.17%
controls:0.17%
cases:51.91%
controls:1.19%
51
35
262
3092
100
14
213
3113
—
10
0
303
3127
—
92
5
194
2999
95
28
88
2332
Cystoscopy
UKC02 [2001306005]
2.6e+00
4.5e+00
—
—
—
5.4e+00
4.3e+00
cases:30.67%
controls:3.29%
cases:46.65%
controls:0.96%
—
—
—
—
—
—
cases:65.38%
controls:0.87%
cases:71.04%
controls:3.18%
96
103
217
3024
146
30
167
3097
—
—
—
187
26
99
2978
130
75
53
2285
Unspecified haematuria
R31 [45553726]
2.3e+00
4.2e+00
—
—
4.0e+00
3.1e+00
1.8e+00
cases:18.21%
controls:2.14%
cases:33.87%
controls:0.74%
—
—
—
—
cases:7.74%
controls:0.16%
cases:12.94%
controls:0.67%
cases:10.93%
controls:1.99%
57
67
256
3060
106
23
207
3104
—
—
24
5
286
3113
37
20
249
2984
20
47
163
2313
Bacteria identified in Urine by Culture
630-4 [3026008]
9.2e-01
2.2e+00
3.7e+00
—
3.2e+00
2.6e+00
1.7e+00
cases:18.53%
controls:8.31%
cases:26.20%
controls:3.87%
cases:16.61%
controls:0.48%
—
—
cases:15.16%
controls:0.71%
cases:34.97%
controls:3.79%
cases:44.81%
controls:13.39%
58
260
255
2867
82
121
231
3006
52
15
261
3112
—
47
22
263
3096
100
114
186
2890
82
316
101
2044
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
9.1e-01
2.3e+00
3.6e+00
—
3.3e+00
2.3e+00
1.8e+00
cases:23.32%
controls:10.94%
cases:34.19%
controls:5.15%
cases:21.09%
controls:0.70%
—
—
cases:15.48%
controls:0.64%
cases:36.01%
controls:5.26%
cases:53.01%
controls:15.93%
73
342
240
2785
107
161
206
2966
66
22
247
3105
—
48
20
262
3098
103
158
183
2846
97
376
86
1984
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
8.2e-01
2.3e+00
3.7e+00
—
3.5e+00
2.2e+00
1.6e+00
cases:18.85%
controls:9.31%
cases:31.63%
controls:4.45%
cases:20.45%
controls:0.64%
—
—
cases:15.81%
controls:0.55%
cases:32.52%
controls:5.26%
cases:46.45%
controls:15.21%
59
291
254
2836
99
139
214
2988
64
20
249
3107
—
49
17
261
3101
93
158
193
2846
85
359
98
2001
General anaesthesia
WX402 [2001310806]
1.2e+00
2.5e+00
2.9e+00
1.0e+50
3.7e+00
2.5e+00
1.2e+00
cases:5.11%
controls:1.66%
cases:8.63%
controls:0.80%
cases:2.88%
controls:0.16%
cases:6.39%
controls:0.00%
cases:6.13%
controls:0.16%
cases:8.74%
controls:0.80%
cases:12.02%
controls:3.77%
16
52
297
3075
27
25
286
3102
9
5
304
3122
20
0
293
3127
19
5
291
3113
25
24
261
2980
22
89
161
2271
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
7.8e-01
2.2e+00
4.0e+00
—
3.5e+00
2.0e+00
1.5e+00
cases:15.65%
controls:7.83%
cases:25.24%
controls:3.77%
cases:19.17%
controls:0.45%
—
—
cases:14.84%
controls:0.55%
cases:27.27%
controls:4.63%
cases:40.98%
controls:13.05%
49
245
264
2882
79
118
234
3009
60
14
253
3113
—
46
17
264
3101
78
139
208
2865
75
308
108
2052
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
1.2e+00
2.1e+00
4.0e+00
—
3.6e+00
1.8e+00
1.2e+00
cases:9.90%
controls:3.29%
cases:14.70%
controls:2.05%
cases:12.14%
controls:0.26%
—
—
cases:8.71%
controls:0.26%
cases:13.29%
controls:2.43%
cases:23.50%
controls:8.31%
31
103
282
3024
46
64
267
3063
38
8
275
3119
—
27
8
283
3110
38
73
248
2931
43
196
140
2164
Bacteria [Presence] in Urine
87829-8 [36304419]
6.8e-01
2.1e+00
4.0e+00
—
3.5e+00
2.1e+00
1.5e+00
cases:14.06%
controls:7.64%
cases:22.68%
controls:3.52%
cases:17.89%
controls:0.42%
—
—
cases:12.90%
controls:0.45%
cases:25.17%
controls:4.13%
cases:38.80%
controls:11.95%
44
239
269
2888
71
110
242
3017
56
13
257
3114
—
40
14
270
3104
72
124
214
2880
71
282
112
2078
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
1.1e+00
2.1e+00
4.3e+00
—
3.3e+00
1.8e+00
1.3e+00
cases:8.63%
controls:3.17%
cases:14.06%
controls:1.92%
cases:12.14%
controls:0.19%
—
—
cases:8.06%
controls:0.32%
cases:13.29%
controls:2.56%
cases:26.23%
controls:8.98%
27
99
286
3028
44
60
269
3067
38
6
275
3121
—
25
10
285
3108
38
77
248
2927
48
212
135
2148
Outpatient Visit
OP [9202]
6.1e-01
1.1e+00
1.5e+00
4.9e+00
1.8e+00
2.2e+00
1.5e+00
cases:88.18%
controls:80.14%
cases:81.79%
controls:59.64%
cases:37.70%
controls:11.80%
cases:36.74%
controls:0.42%
cases:40.97%
controls:10.55%
cases:93.36%
controls:61.32%
cases:96.72%
controls:87.16%
276
2506
37
621
256
1865
57
1262
118
369
195
2758
115
13
198
3114
127
329
183
2789
267
1842
19
1162
177
2057
6
303
Leukocytes [#/volume] in Urine
30405-5 [3018095]
7.8e-01
2.2e+00
3.6e+00
—
3.3e+00
2.0e+00
1.5e+00
cases:19.17%
controls:9.82%
cases:31.63%
controls:4.76%
cases:20.45%
controls:0.70%
—
—
cases:16.45%
controls:0.71%
cases:33.22%
controls:6.16%
cases:46.99%
controls:17.20%
60
307
253
2820
99
149
214
2978
64
22
249
3105
—
51
22
259
3096
95
185
191
2819
86
406
97
1954
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
7.0e-01
2.2e+00
3.2e+00
—
3.2e+00
2.3e+00
1.7e+00
cases:12.46%
controls:6.62%
cases:18.53%
controls:2.53%
cases:9.27%
controls:0.42%
—
—
cases:7.74%
controls:0.35%
cases:22.38%
controls:2.76%
cases:31.69%
controls:7.67%
39
207
274
2920
58
79
255
3048
29
13
284
3114
—
24
11
286
3107
64
83
222
2921
58
181
125
2179
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.9e-01
2.0e+00
3.8e+00
—
3.2e+00
2.0e+00
1.7e+00
cases:32.59%
controls:21.07%
cases:44.41%
controls:10.01%
cases:37.06%
controls:1.34%
—
—
cases:25.81%
controls:1.38%
cases:48.95%
controls:11.05%
cases:67.76%
controls:28.43%
102
659
211
2468
139
313
174
2814
116
42
197
3085
—
80
43
230
3075
140
332
146
2672
124
671
59
1689
Inpatient Visit
IP [9201]
8.5e-01
1.9e+00
2.5e+00
1.0e+50
4.2e+00
2.5e+00
1.3e+00
cases:15.65%
controls:7.36%
cases:20.45%
controls:3.87%
cases:6.07%
controls:0.51%
cases:11.50%
controls:0.00%
cases:12.90%
controls:0.22%
cases:29.72%
controls:3.43%
cases:33.88%
controls:12.50%
49
230
264
2897
64
121
249
3006
19
16
294
3111
36
0
277
3127
40
7
270
3111
85
103
201
2901
62
295
121
2065
Oncology Clinic/Center
261QX0200X [38004268]
4.7e+00
4.9e+00
1.0e+50
1.0e+50
1.0e+50
—
3.6e+00
cases:26.20%
controls:0.32%
cases:23.00%
controls:0.22%
cases:7.99%
controls:0.00%
cases:29.71%
controls:0.00%
cases:5.81%
controls:0.00%
—
—
cases:15.30%
controls:0.51%
82
10
231
3117
72
7
241
3120
25
0
288
3127
93
0
220
3127
18
0
292
3118
—
28
12
155
2348
Tissue Pathology biopsy report
66121-5 [40768804]
1.1e+00
2.3e+00
2.3e+00
1.0e+50
3.5e+00
2.4e+00
1.6e+00
cases:17.57%
controls:6.65%
cases:21.09%
controls:2.53%
cases:3.83%
controls:0.42%
cases:10.22%
controls:0.00%
cases:10.65%
controls:0.35%
cases:18.53%
controls:2.10%
cases:27.87%
controls:7.50%
55
208
258
2919
66
79
247
3048
12
13
301
3114
32
0
281
3127
33
11
277
3107
53
63
233
2941
51
177
132
2183
Osmolality of Urine
2695-5 [3026782]
7.0e-01
1.8e+00
3.4e+00
—
3.4e+00
2.0e+00
1.5e+00
cases:12.78%
controls:6.81%
cases:15.65%
controls:2.85%
cases:8.95%
controls:0.32%
—
—
cases:8.06%
controls:0.29%
cases:17.48%
controls:2.83%
cases:24.04%
controls:6.82%
40
213
273
2914
49
89
264
3038
28
10
285
3117
—
25
9
285
3109
50
85
236
2919
44
161
139
2199
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
5.2e-01
1.8e+00
3.6e+00
1.0e+50
3.8e+00
2.1e+00
8.5e-01
cases:16.93%
controls:10.84%
cases:21.41%
controls:4.35%
cases:13.42%
controls:0.42%
cases:3.51%
controls:0.00%
cases:15.48%
controls:0.42%
cases:24.13%
controls:3.79%
cases:26.78%
controls:13.56%
53
339
260
2788
67
136
246
2991
42
13
271
3114
11
0
302
3127
48
13
262
3105
69
114
217
2890
49
320
134
2040
Pathology report gross observation
24419-4 [3002256]
1.9e+00
3.4e+00
—
1.0e+50
—
4.1e+00
2.4e+00
cases:7.67%
controls:1.25%
cases:9.27%
controls:0.35%
—
—
cases:4.15%
controls:0.00%
—
—
cases:12.59%
controls:0.23%
cases:15.85%
controls:1.65%
24
39
289
3088
29
11
284
3116
—
13
0
300
3127
—
36
7
250
2997
29
39
154
2321
Teaching
WZC30 [2001310891]
1.0e+00
1.3e+00
2.4e+00
—
2.8e+00
2.6e+00
1.4e+00
cases:6.07%
controls:2.30%
cases:3.83%
controls:1.06%
cases:2.88%
controls:0.26%
—
—
cases:2.58%
controls:0.16%
cases:9.44%
controls:0.80%
cases:10.38%
controls:2.71%
19
72
294
3055
12
33
301
3094
9
8
304
3119
—
8
5
302
3113
27
24
259
2980
19
64
164
2296
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
5.7e-01
1.6e+00
3.1e+00
1.0e+50
3.6e+00
2.3e+00
8.6e-01
cases:12.46%
controls:7.45%
cases:13.42%
controls:3.04%
cases:6.71%
controls:0.32%
cases:2.24%
controls:0.00%
cases:9.35%
controls:0.29%
cases:19.23%
controls:2.40%
cases:18.58%
controls:8.81%
39
233
274
2894
42
95
271
3032
21
10
292
3117
7
0
306
3127
29
9
281
3109
55
72
231
2932
34
208
149
2152
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
4.7e-01
1.7e+00
2.9e+00
1.0e+50
3.6e+00
2.2e+00
8.5e-01
cases:8.63%
controls:5.56%
cases:10.54%
controls:2.17%
cases:4.79%
controls:0.29%
cases:2.56%
controls:0.00%
cases:7.74%
controls:0.22%
cases:15.03%
controls:1.90%
cases:15.30%
controls:7.16%
27
174
286
2953
33
68
280
3059
15
9
298
3118
8
0
305
3127
24
7
286
3111
43
57
243
2947
28
169
155
2191
Outpatient Hospital
22 [8756]
5.3e-01
1.8e+00
2.0e+00
1.0e+50
3.2e+00
2.2e+00
1.4e+00
cases:39.30%
controls:27.50%
cases:32.27%
controls:7.42%
cases:7.35%
controls:1.06%
cases:18.21%
controls:0.00%
cases:17.74%
controls:0.90%
cases:36.01%
controls:5.96%
cases:44.26%
controls:15.72%
123
860
190
2267
101
232
212
2895
23
33
290
3094
57
0
256
3127
55
28
255
3090
103
179
183
2825
81
371
102
1989
Urinary tract ultrasound examination
KH1AE [2001306329]
2.2e+00
3.5e+00
—
—
—
3.3e+00
2.0e+00
cases:5.75%
controls:0.64%
cases:6.71%
controls:0.22%
—
—
—
—
—
—
cases:4.55%
controls:0.17%
cases:9.84%
controls:1.40%
18
20
295
3107
21
7
292
3120
—
—
—
13
5
273
2999
18
33
165
2327
Body CT examination
JN4AD [2001310897]
2.1e+00
2.7e+00
—
—
1.0e+50
3.2e+00
2.9e+00
cases:4.15%
controls:0.51%
cases:3.83%
controls:0.26%
—
—
—
—
cases:2.58%
controls:0.00%
cases:10.14%
controls:0.47%
cases:20.22%
controls:1.31%
13
16
300
3111
12
8
301
3119
—
—
8
0
302
3118
29
14
257
2990
37
31
146
2329
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
5.6e-01
1.6e+00
3.1e+00
—
2.6e+00
1.8e+00
1.3e+00
cases:33.55%
controls:22.35%
cases:38.02%
controls:11.35%
cases:20.77%
controls:1.22%
—
—
cases:16.77%
controls:1.44%
cases:43.01%
controls:11.52%
cases:58.47%
controls:27.50%
105
699
208
2428
119
355
194
2772
65
38
248
3089
—
52
45
258
3073
123
346
163
2658
107
649
76
1711
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.2e+00
2.3e+00
2.9e+00
—
—
2.4e+00
1.5e+00
cases:19.17%
controls:6.56%
cases:17.57%
controls:2.05%
cases:3.51%
controls:0.19%
—
—
—
—
cases:16.78%
controls:1.86%
cases:24.59%
controls:6.99%
60
205
253
2922
55
64
258
3063
11
6
302
3121
—
—
48
56
238
2948
45
165
138
2195
More than one and less than three hours
ZXE10 [2001311401]
8.3e-01
2.0e+00
—
1.0e+50
3.0e+00
2.5e+00
1.7e+00
cases:13.74%
controls:6.52%
cases:10.22%
controls:1.57%
—
—
cases:5.11%
controls:0.00%
cases:4.52%
controls:0.22%
cases:10.84%
controls:1.00%
cases:13.11%
controls:2.80%
43
204
270
2923
32
49
281
3078
—
16
0
297
3127
14
7
296
3111
31
30
255
2974
24
66
159
2294
General Surgery
2 [38004447]
5.7e-01
1.4e+00
2.5e+00
1.0e+50
2.8e+00
1.7e+00
8.9e-01
cases:26.84%
controls:17.17%
cases:15.97%
controls:4.64%
cases:5.75%
controls:0.51%
cases:4.47%
controls:0.00%
cases:7.10%
controls:0.45%
cases:19.93%
controls:4.33%
cases:26.78%
controls:13.05%
84
537
229
2590
50
145
263
2982
18
16
295
3111
14
0
299
3127
22
14
288
3104
57
130
229
2874
49
308
134
2052
tinzaparin; parenteral
B01AB10 [21600981]
1.7e+00
2.7e+00
—
—
—
3.4e+00
1.9e+00
cases:3.51%
controls:0.67%
cases:4.47%
controls:0.32%
—
—
—
—
—
—
cases:10.14%
controls:0.37%
cases:10.38%
controls:1.65%
11
21
302
3106
14
10
299
3117
—
—
—
29
11
257
2993
19
39
164
2321
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.5e-01
7.9e-01
2.4e+00
3.3e+00
2.3e+00
8.3e-01
3.8e-01
cases:41.53%
controls:33.35%
cases:46.96%
controls:28.72%
cases:35.78%
controls:4.86%
cases:6.71%
controls:0.26%
cases:36.13%
controls:5.42%
cases:50.70%
controls:30.96%
cases:62.30%
controls:53.09%
130
1043
183
2084
147
898
166
2229
112
152
201
2975
21
8
292
3119
112
169
198
2949
145
930
141
2074
114
1253
69
1107
Catheterisation of bladder
TKC20 [2001306020]
1.5e+00
2.7e+00
—
—
—
3.1e+00
2.3e+00
cases:4.79%
controls:1.12%
cases:6.39%
controls:0.45%
—
—
—
—
—
—
cases:6.99%
controls:0.33%
cases:8.20%
controls:0.89%
15
35
298
3092
20
14
293
3113
—
—
—
20
10
266
2994
15
21
168
2339
Spinalanesthesia
WX320 [2001310799]
1.0e+00
2.0e+00
—
1.0e+50
2.5e+00
2.6e+00
1.5e+00
cases:12.78%
controls:5.02%
cases:9.27%
controls:1.34%
—
—
cases:2.88%
controls:0.00%
cases:2.26%
controls:0.19%
cases:11.89%
controls:1.03%
cases:16.39%
controls:4.32%
40
157
273
2970
29
42
284
3085
—
9
0
304
3127
7
6
303
3112
34
31
252
2973
30
102
153
2258
General anesthesia, balanced
WX408 [2001310808]
1.4e+00
2.4e+00
—
1.0e+50
—
3.3e+00
2.5e+00
cases:13.10%
controls:3.74%
cases:9.27%
controls:0.93%
—
—
cases:9.58%
controls:0.00%
—
—
cases:13.64%
controls:0.60%
cases:15.30%
controls:1.44%
41
117
272
3010
29
29
284
3098
—
30
0
283
3127
—
39
18
247
2986
28
34
155
2326
Abdominal ultrasound examination
JN3AE [2001305555]
1.3e+00
2.5e+00
—
1.0e+50
—
3.1e+00
2.5e+00
cases:5.11%
controls:1.44%
cases:4.15%
controls:0.35%
—
—
cases:1.60%
controls:0.00%
—
—
cases:9.44%
controls:0.47%
cases:15.30%
controls:1.48%
16
45
297
3082
13
11
300
3116
—
5
0
308
3127
—
27
14
259
2990
28
35
155
2325
CT of urinary organs
KH1AD [2001306328]
2.2e+00
4.0e+00
—
—
—
—
3.0e+00
cases:3.83%
controls:0.45%
cases:8.31%
controls:0.16%
—
—
—
—
—
—
—
—
cases:7.65%
controls:0.42%
12
14
301
3113
26
5
287
3122
—
—
—
—
14
10
169
2350
Intravenous general anesthesia
WX404 [2001310807]
1.3e+00
1.8e+00
—
—
—
3.2e+00
2.8e+00
cases:8.95%
controls:2.56%
cases:4.47%
controls:0.74%
—
—
—
—
—
—
cases:6.99%
controls:0.30%
cases:11.48%
controls:0.81%
28
80
285
3047
14
23
299
3104
—
—
—
20
9
266
2995
21
19
162
2341
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5.5e-01
1.4e+00
2.8e+00
1.0e+50
2.5e+00
1.5e+00
9.6e-01
cases:10.22%
controls:6.14%
cases:11.18%
controls:3.13%
cases:4.79%
controls:0.32%
cases:1.60%
controls:0.00%
cases:6.77%
controls:0.58%
cases:10.14%
controls:2.40%
cases:18.58%
controls:8.05%
32
192
281
2935
35
98
278
3029
15
10
298
3117
5
0
308
3127
21
18
289
3100
29
72
257
2932
34
190
149
2170
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
7.0e-01
1.2e+00
2.3e+00
—
2.5e+00
1.9e+00
1.3e+00
cases:5.43%
controls:2.78%
cases:5.11%
controls:1.63%
cases:2.56%
controls:0.26%
—
—
cases:5.16%
controls:0.45%
cases:9.79%
controls:1.66%
cases:13.66%
controls:4.28%
17
87
296
3040
16
51
297
3076
8
8
305
3119
—
16
14
294
3104
28
50
258
2954
25
101
158
2259
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.8e-01
6.6e-01
2.3e+00
3.3e+00
2.2e+00
6.6e-01
3.0e-01
cases:53.67%
controls:49.28%
cases:57.83%
controls:41.38%
cases:45.69%
controls:7.58%
cases:7.67%
controls:0.32%
cases:43.23%
controls:7.99%
cases:60.84%
controls:44.61%
cases:73.77%
controls:67.54%
168
1541
145
1586
181
1294
132
1833
143
237
170
2890
24
10
289
3117
134
249
176
2869
174
1340
112
1664
135
1594
48
766
trimethoprim; oral, parenteral
J01EA01 [21602931]
1.0e+00
1.7e+00
1.6e+00
—
3.0e+00
2.2e+00
1.2e+00
cases:14.06%
controls:5.60%
cases:11.50%
controls:2.40%
cases:1.60%
controls:0.32%
—
—
cases:6.13%
controls:0.32%
cases:16.08%
controls:2.10%
cases:20.22%
controls:7.29%
44
175
269
2952
36
75
277
3052
5
10
308
3117
—
19
10
291
3108
46
63
240
2941
37
172
146
2188
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.8e-01
6.2e-01
2.1e+00
3.4e+00
2.2e+00
6.8e-01
3.0e-01
cases:51.76%
controls:47.20%
cases:53.67%
controls:38.28%
cases:35.78%
controls:6.62%
cases:9.90%
controls:0.35%
cases:39.68%
controls:6.54%
cases:57.34%
controls:40.58%
cases:71.58%
controls:65.17%
162
1476
151
1651
168
1197
145
1930
112
207
201
2920
31
11
282
3116
123
204
187
2914
164
1219
122
1785
131
1538
52
822
Inpatient Hospital
21 [8717]
4.8e-01
1.4e+00
1.8e+00
—
2.7e+00
1.6e+00
1.1e+00
cases:45.69%
controls:34.22%
cases:34.82%
controls:11.77%
cases:8.63%
controls:1.57%
—
—
cases:20.00%
controls:1.70%
cases:37.41%
controls:10.55%
cases:47.54%
controls:24.03%
143
1070
170
2057
109
368
204
2759
27
49
286
3078
—
62
53
248
3065
107
317
179
2687
87
567
96
1793
Thorax X-ray examination
GD1AA [2001303617]
4.7e-01
7.4e-01
2.3e+00
—
2.6e+00
2.0e+00
1.3e+00
cases:18.85%
controls:12.70%
cases:9.58%
controls:4.83%
cases:3.51%
controls:0.35%
—
—
cases:4.52%
controls:0.35%
cases:24.48%
controls:4.09%
cases:38.25%
controls:14.70%
59
397
254
2730
30
151
283
2976
11
11
302
3116
—
14
11
296
3107
70
123
216
2881
70
347
113
2013
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.7e-01
6.1e-01
2.0e+00
3.4e+00
2.2e+00
6.7e-01
2.8e-01
cases:51.76%
controls:47.49%
cases:53.67%
controls:38.73%
cases:36.10%
controls:6.84%
cases:9.27%
controls:0.35%
cases:40.00%
controls:6.74%
cases:57.69%
controls:41.11%
cases:71.58%
controls:65.51%
162
1485
151
1642
168
1211
145
1916
113
214
200
2913
29
11
284
3116
124
210
186
2908
165
1235
121
1769
131
1546
52
814
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.2e-01
8.6e-01
1.7e+00
2.8e+00
2.2e+00
1.2e+00
4.4e-01
cases:41.53%
controls:38.73%
cases:42.81%
controls:24.11%
cases:20.13%
controls:4.22%
cases:4.47%
controls:0.29%
cases:28.06%
controls:3.98%
cases:51.75%
controls:24.27%
cases:62.30%
controls:51.53%
130
1211
183
1916
134
754
179
2373
63
132
250
2995
14
9
299
3118
87
124
223
2994
148
729
138
2275
114
1216
69
1144
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
3.5e-01
1.4e+00
2.7e+00
—
2.6e+00
1.2e+00
8.3e-01
cases:10.54%
controls:7.64%
cases:14.38%
controls:3.84%
cases:6.71%
controls:0.48%
—
—
cases:5.48%
controls:0.45%
cases:12.24%
controls:4.03%
cases:20.77%
controls:10.30%
33
239
280
2888
45
120
268
3007
21
15
292
3112
—
17
14
293
3104
35
121
251
2883
38
243
145
2117
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.4e+00
1.9e+00
—
—
1.0e+50
3.1e+00
2.3e+00
cases:5.11%
controls:1.31%
cases:3.19%
controls:0.51%
—
—
—
—
cases:3.55%
controls:0.00%
cases:11.54%
controls:0.57%
cases:10.93%
controls:1.23%
16
41
297
3086
10
16
303
3111
—
—
11
0
299
3118
33
17
253
2987
20
29
163
2331
Upper gastrointestinal surgery
106 [44777669]
6.1e-01
1.3e+00
1.8e+00
—
1.9e+00
1.7e+00
1.3e+00
cases:17.57%
controls:10.43%
cases:13.10%
controls:3.90%
cases:3.83%
controls:0.64%
—
—
cases:3.23%
controls:0.51%
cases:18.18%
controls:3.73%
cases:32.24%
controls:11.48%
55
326
258
2801
41
122
272
3005
12
20
301
3107
—
10
16
300
3102
52
112
234
2892
59
271
124
2089
Laboratory Visit
OMOP4822461 [32036]
1.1e-01
5.2e-01
2.1e+00
3.8e+00
1.8e+00
5.0e-01
2.7e-01
cases:56.23%
controls:53.44%
cases:62.30%
controls:49.66%
cases:57.83%
controls:14.90%
cases:27.48%
controls:0.83%
cases:51.61%
controls:15.55%
cases:64.69%
controls:52.56%
cases:76.50%
controls:71.27%
176
1671
137
1456
195
1553
118
1574
181
466
132
2661
86
26
227
3101
160
485
150
2633
185
1579
101
1425
140
1682
43
678
CBC panel - Blood by Automated count
58410-2 [40761511]
1.8e-01
6.0e-01
2.2e+00
3.2e+00
2.0e+00
6.0e-01
2.3e-01
cases:47.28%
controls:42.79%
cases:41.85%
controls:28.37%
cases:27.48%
controls:4.22%
cases:6.07%
controls:0.26%
cases:28.06%
controls:4.81%
cases:41.26%
controls:27.90%
cases:56.28%
controls:50.59%
148
1338
165
1789
131
887
182
2240
86
132
227
2995
19
8
294
3119
87
150
223
2968
118
838
168
2166
103
1194
80
1166
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.4e-01
6.0e-01
2.1e+00
3.1e+00
2.2e+00
6.3e-01
2.3e-01
cases:53.67%
controls:50.30%
cases:57.83%
controls:42.82%
cases:40.58%
controls:7.90%
cases:9.58%
controls:0.48%
cases:44.19%
controls:8.05%
cases:60.49%
controls:44.81%
cases:73.22%
controls:68.43%
168
1573
145
1554
181
1339
132
1788
127
247
186
2880
30
15
283
3112
137
251
173
2867
173
1346
113
1658
134
1615
49
745
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
4.6e-01
1.0e+00
2.2e+00
—
2.5e+00
1.6e+00
8.0e-01
cases:25.56%
controls:17.75%
cases:21.73%
controls:9.15%
cases:10.54%
controls:1.28%
—
—
cases:12.26%
controls:1.15%
cases:28.32%
controls:7.62%
cases:42.08%
controls:24.53%
80
555
233
2572
68
286
245
2841
33
40
280
3087
—
38
36
272
3082
81
229
205
2775
77
579
106
1781
Cathetrisation of artery
TPH07 [2001309747]
1.4e+00
2.4e+00
—
1.0e+50
—
3.0e+00
1.6e+00
cases:3.51%
controls:0.90%
cases:3.19%
controls:0.29%
—
—
cases:3.51%
controls:0.00%
—
—
cases:9.44%
controls:0.50%
cases:9.29%
controls:1.95%
11
28
302
3099
10
9
303
3118
—
11
0
302
3127
—
27
15
259
2989
17
46
166
2314
MCH [Entitic mass]
28539-5 [3035941]
1.2e-01
6.1e-01
2.1e+00
2.9e+00
2.2e+00
6.4e-01
2.3e-01
cases:53.35%
controls:50.24%
cases:57.83%
controls:42.76%
cases:40.58%
controls:7.83%
cases:8.31%
controls:0.48%
cases:44.19%
controls:8.05%
cases:60.49%
controls:44.77%
cases:73.22%
controls:68.43%
167
1571
146
1556
181
1337
132
1790
127
245
186
2882
26
15
287
3112
137
251
173
2867
173
1345
113
1659
134
1615
49
745
Platelets [#/volume] in Blood
26515-7 [3007461]
1.4e-01
6.1e-01
2.1e+00
2.9e+00
2.2e+00
6.3e-01
2.3e-01
cases:53.67%
controls:50.24%
cases:57.83%
controls:42.69%
cases:40.58%
controls:7.83%
cases:8.31%
controls:0.48%
cases:44.19%
controls:8.05%
cases:60.49%
controls:44.87%
cases:73.22%
controls:68.47%
168
1571
145
1556
181
1335
132
1792
127
245
186
2882
26
15
287
3112
137
251
173
2867
173
1348
113
1656
134
1616
49
744
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.2e-01
6.1e-01
2.1e+00
2.9e+00
2.2e+00
6.3e-01
2.3e-01
cases:53.35%
controls:50.27%
cases:57.83%
controls:42.79%
cases:40.58%
controls:7.90%
cases:8.31%
controls:0.48%
cases:44.19%
controls:8.05%
cases:60.49%
controls:44.84%
cases:73.22%
controls:68.47%
167
1572
146
1555
181
1338
132
1789
127
247
186
2880
26
15
287
3112
137
251
173
2867
173
1347
113
1657
134
1616
49
744
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.4e-01
6.1e-01
2.1e+00
2.9e+00
2.2e+00
6.3e-01
2.3e-01
cases:53.67%
controls:50.24%
cases:57.83%
controls:42.79%
cases:40.26%
controls:7.83%
cases:8.31%
controls:0.48%
cases:44.19%
controls:8.05%
cases:60.49%
controls:44.81%
cases:73.22%
controls:68.47%
168
1571
145
1556
181
1338
132
1789
126
245
187
2882
26
15
287
3112
137
251
173
2867
173
1346
113
1658
134
1616
49
744
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.4e-01
6.0e-01
2.1e+00
2.9e+00
2.2e+00
6.3e-01
2.3e-01
cases:53.67%
controls:50.30%
cases:57.83%
controls:42.85%
cases:40.58%
controls:7.90%
cases:8.31%
controls:0.48%
cases:44.19%
controls:8.05%
cases:60.49%
controls:44.87%
cases:73.22%
controls:68.47%
168
1573
145
1554
181
1340
132
1787
127
247
186
2880
26
15
287
3112
137
251
173
2867
173
1348
113
1656
134
1616
49
744
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.5e-01
6.0e-01
2.1e+00
2.9e+00
2.2e+00
6.3e-01
2.3e-01
cases:53.99%
controls:50.27%
cases:57.83%
controls:42.82%
cases:40.58%
controls:7.93%
cases:8.31%
controls:0.48%
cases:44.19%
controls:8.05%
cases:60.49%
controls:44.81%
cases:73.22%
controls:68.47%
169
1572
144
1555
181
1339
132
1788
127
248
186
2879
26
15
287
3112
137
251
173
2867
173
1346
113
1658
134
1616
49
744
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
1.6e-01
1.4e+00
2.6e+00
—
2.3e+00
1.2e+00
8.6e-01
cases:16.61%
controls:14.45%
cases:24.92%
controls:7.45%
cases:12.46%
controls:1.02%
—
—
cases:9.68%
controls:1.06%
cases:24.83%
controls:8.85%
cases:43.17%
controls:24.28%
52
452
261
2675
78
233
235
2894
39
32
274
3095
—
30
33
280
3085
71
266
215
2738
79
573
104
1787
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
1.6e-01
1.4e+00
2.6e+00
—
2.3e+00
1.2e+00
8.5e-01
cases:15.97%
controls:13.94%
cases:23.96%
controls:7.29%
cases:12.46%
controls:1.02%
—
—
cases:9.68%
controls:1.09%
cases:24.83%
controls:8.72%
cases:42.08%
controls:23.77%
50
436
263
2691
75
228
238
2899
39
32
274
3095
—
30
34
280
3084
71
262
215
2742
77
561
106
1799
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2.4e-01
1.4e+00
2.7e+00
—
2.3e+00
1.2e+00
8.0e-01
cases:17.25%
controls:14.07%
cases:24.60%
controls:7.42%
cases:12.46%
controls:0.99%
—
—
cases:10.00%
controls:1.15%
cases:24.83%
controls:8.92%
cases:41.53%
controls:24.24%
54
440
259
2687
77
232
236
2895
39
31
274
3096
—
31
36
279
3082
71
268
215
2736
76
572
107
1788
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
-1.3e-01
1.3e+00
2.8e+00
—
2.1e+00
1.4e+00
7.2e-01
cases:7.99%
controls:9.02%
cases:15.02%
controls:4.57%
cases:7.35%
controls:0.48%
—
—
cases:4.84%
controls:0.64%
cases:17.48%
controls:4.99%
cases:23.50%
controls:13.05%
25
282
288
2845
47
143
266
2984
23
15
290
3112
—
15
20
295
3098
50
150
236
2854
43
308
140
2052
Microorganisms panel - Urine sediment
58435-9 [40761536]
4.4e-01
1.6e+00
2.7e+00
—
2.7e+00
1.3e+00
1.3e+00
cases:3.83%
controls:2.49%
cases:6.07%
controls:1.25%
cases:2.24%
controls:0.16%
—
—
cases:2.26%
controls:0.16%
cases:3.85%
controls:1.13%
cases:8.74%
controls:2.58%
12
78
301
3049
19
39
294
3088
7
5
306
3122
—
7
5
303
3113
11
34
275
2970
16
61
167
2299
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
8.5e-01
2.3e+00
2.6e+00
—
—
2.2e+00
1.1e+00
cases:4.15%
controls:1.82%
cases:8.31%
controls:0.90%
cases:2.56%
controls:0.19%
—
—
—
—
cases:8.39%
controls:1.03%
cases:11.48%
controls:4.03%
13
57
300
3070
26
28
287
3099
8
6
305
3121
—
—
24
31
262
2973
21
95
162
2265
pH of Urine
2756-5 [3015736]
9.5e-02
1.4e+00
2.7e+00
—
2.3e+00
1.1e+00
8.3e-01
cases:12.14%
controls:11.16%
cases:17.57%
controls:5.18%
cases:9.58%
controls:0.74%
—
—
cases:7.42%
controls:0.83%
cases:16.08%
controls:6.26%
cases:32.79%
controls:17.58%
38
349
275
2778
55
162
258
2965
30
23
283
3104
—
23
26
287
3092
46
188
240
2816
60
415
123
1945
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
9.6e-01
2.1e+00
2.2e+00
—
—
1.9e+00
1.0e+00
cases:5.43%
controls:2.14%
cases:7.67%
controls:1.06%
cases:2.56%
controls:0.29%
—
—
—
—
cases:9.79%
controls:1.63%
cases:13.66%
controls:5.51%
17
67
296
3060
24
33
289
3094
8
9
305
3118
—
—
28
49
258
2955
25
130
158
2230
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
4.1e-01
1.1e+00
1.9e+00
—
2.3e+00
1.6e+00
1.0e+00
cases:17.57%
controls:12.41%
cases:17.57%
controls:6.36%
cases:5.11%
controls:0.80%
—
—
cases:7.10%
controls:0.77%
cases:24.48%
controls:5.93%
cases:37.70%
controls:17.63%
55
388
258
2739
55
199
258
2928
16
25
297
3102
—
22
24
288
3094
70
178
216
2826
69
416
114
1944
Treatment plan or consultation
WZC00 [2001310885]
9.4e-01
1.4e+00
2.5e+00
—
—
1.9e+00
1.3e+00
cases:10.86%
controls:4.54%
cases:6.39%
controls:1.66%
cases:2.24%
controls:0.19%
—
—
—
—
cases:10.49%
controls:1.76%
cases:18.58%
controls:5.89%
34
142
279
2985
20
52
293
3075
7
6
306
3121
—
—
30
53
256
2951
34
139
149
2221
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.5e-01
4.4e-01
1.9e+00
2.8e+00
2.0e+00
6.0e-01
2.1e-01
cases:33.55%
controls:30.25%
cases:35.14%
controls:25.87%
cases:25.56%
controls:4.67%
cases:6.07%
controls:0.38%
cases:30.32%
controls:5.36%
cases:39.51%
controls:26.33%
cases:51.37%
controls:46.06%
105
946
208
2181
110
809
203
2318
80
146
233
2981
19
12
294
3115
94
167
216
2951
113
791
173
2213
94
1087
89
1273
INR in Blood by Coagulation assay
34714-6 [3032080]
4.3e-01
9.1e-01
1.1e+00
2.6e+00
1.2e+00
1.2e+00
7.8e-01
cases:24.28%
controls:17.24%
cases:22.36%
controls:10.43%
cases:11.18%
controls:4.19%
cases:2.88%
controls:0.22%
cases:11.94%
controls:3.94%
cases:27.27%
controls:10.29%
cases:38.25%
controls:22.12%
76
539
237
2588
70
326
243
2801
35
131
278
2996
9
7
304
3120
37
123
273
2995
78
309
208
2695
70
522
113
1838
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
1.9e-02
1.3e+00
2.5e+00
—
2.2e+00
1.0e+00
6.1e-01
cases:12.78%
controls:12.57%
cases:18.85%
controls:6.24%
cases:9.27%
controls:0.80%
—
—
cases:6.77%
controls:0.80%
cases:16.43%
controls:6.52%
cases:27.32%
controls:16.95%
40
393
273
2734
59
195
254
2932
29
25
284
3102
—
21
25
289
3093
47
196
239
2808
50
400
133
1960
Scheduled procedure
ZXD10 [2001311387]
1.0e+00
2.1e+00
—
1.0e+50
—
2.7e+00
1.7e+00
cases:17.57%
controls:7.26%
cases:12.14%
controls:1.60%
—
—
cases:6.07%
controls:0.00%
—
—
cases:13.99%
controls:1.03%
cases:14.75%
controls:3.01%
55
227
258
2900
38
50
275
3077
—
19
0
294
3127
—
40
31
246
2973
27
71
156
2289
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
4.6e-01
1.1e+00
2.1e+00
—
2.3e+00
1.3e+00
8.6e-01
cases:16.93%
controls:11.42%
cases:15.97%
controls:6.08%
cases:5.11%
controls:0.67%
—
—
cases:8.71%
controls:0.96%
cases:19.93%
controls:6.36%
cases:33.33%
controls:17.50%
53
357
260
2770
50
190
263
2937
16
21
297
3106
—
27
30
283
3088
57
191
229
2813
61
413
122
1947
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
4.4e-01
1.3e+00
2.2e+00
—
2.4e+00
8.9e-01
7.8e-01
cases:7.99%
controls:5.31%
cases:9.27%
controls:2.81%
cases:5.11%
controls:0.58%
—
—
cases:4.84%
controls:0.45%
cases:8.39%
controls:3.63%
cases:21.86%
controls:11.40%
25
166
288
2961
29
88
284
3039
16
18
297
3109
—
15
14
295
3104
24
109
262
2895
40
269
143
2091
Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
3216-9 [3020427]
1.4e+00
3.0e+00
—
—
—
2.7e+00
1.7e+00
cases:1.92%
controls:0.48%
cases:3.19%
controls:0.16%
—
—
—
—
—
—
cases:2.45%
controls:0.17%
cases:4.92%
controls:0.89%
6
15
307
3112
10
5
303
3122
—
—
—
7
5
279
2999
9
21
174
2339
One hour or less
ZXE00 [2001311394]
1.2e+00
1.9e+00
—
1.0e+50
—
2.7e+00
1.6e+00
cases:19.17%
controls:6.65%
cases:11.50%
controls:1.89%
—
—
cases:3.51%
controls:0.00%
—
—
cases:13.99%
controls:1.10%
cases:17.49%
controls:3.94%
60
208
253
2919
36
59
277
3068
—
11
0
302
3127
—
40
33
246
2971
32
93
151
2267
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
1.3e+00
2.0e+00
—
—
—
2.2e+00
1.9e+00
cases:3.51%
controls:0.99%
cases:3.83%
controls:0.54%
—
—
—
—
—
—
cases:4.55%
controls:0.50%
cases:9.29%
controls:1.57%
11
31
302
3096
12
17
301
3110
—
—
—
13
15
273
2989
17
37
166
2323
Physiotherapy
R4110 [2001310233]
3.3e-01
1.4e+00
—
—
2.5e+00
2.1e+00
1.3e+00
cases:8.31%
controls:6.11%
cases:7.67%
controls:2.05%
—
—
—
—
cases:4.19%
controls:0.35%
cases:11.19%
controls:1.56%
cases:16.39%
controls:5.17%
26
191
287
2936
24
64
289
3063
—
—
13
11
297
3107
32
47
254
2957
30
122
153
2238
Physiotherapist
Z3226 [2001311560]
9.1e-01
9.3e-01
—
—
2.5e+00
2.2e+00
1.6e+00
cases:6.07%
controls:2.53%
cases:1.92%
controls:0.77%
—
—
—
—
cases:1.94%
controls:0.16%
cases:4.90%
controls:0.57%
cases:6.56%
controls:1.40%
19
79
294
3048
6
24
307
3103
—
—
6
5
304
3113
14
17
272
2987
12
33
171
2327
Intravenous
ZX120 [2001311495]
1.1e+00
2.5e+00
—
—
—
2.7e+00
1.8e+00
cases:2.88%
controls:1.02%
cases:2.56%
controls:0.22%
—
—
—
—
—
—
cases:3.50%
controls:0.23%
cases:6.01%
controls:1.02%
9
32
304
3095
8
7
305
3120
—
—
—
10
7
276
2997
11
24
172
2336
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
5.1e-01
1.0e+00
1.6e+00
1.0e+50
2.1e+00
1.1e+00
6.0e-01
cases:20.77%
controls:13.59%
cases:17.25%
controls:7.04%
cases:4.47%
controls:0.90%
cases:3.19%
controls:0.00%
cases:7.74%
controls:1.06%
cases:20.28%
controls:7.66%
cases:32.24%
controls:20.64%
65
425
248
2702
54
220
259
2907
14
28
299
3099
10
0
303
3127
24
33
286
3085
58
230
228
2774
59
487
124
1873
Acute tubulo-interstitial nephritis
N10 [45543856]
9.7e-01
2.1e+00
—
—
—
2.4e+00
1.5e+00
cases:6.07%
controls:2.40%
cases:7.03%
controls:0.93%
—
—
—
—
—
—
cases:8.74%
controls:0.90%
cases:16.94%
controls:4.28%
19
75
294
3052
22
29
291
3098
—
—
—
25
27
261
2977
31
101
152
2259
Medical doctor
Z2221 [2001311556]
1.1e+00
1.8e+00
—
—
—
2.3e+00
1.6e+00
cases:11.82%
controls:4.13%
cases:7.35%
controls:1.28%
—
—
—
—
—
—
cases:9.44%
controls:1.00%
cases:13.11%
controls:2.88%
37
129
276
2998
23
40
290
3087
—
—
—
27
30
259
2974
24
68
159
2292
Bacteria identified in Blood by Culture
600-7 [3023368]
5.7e-01
1.5e+00
1.5e+00
—
2.8e+00
1.7e+00
8.3e-01
cases:11.50%
controls:6.84%
cases:11.50%
controls:2.94%
cases:1.60%
controls:0.35%
—
—
cases:7.10%
controls:0.45%
cases:16.43%
controls:3.43%
cases:23.50%
controls:11.82%
36
214
277
2913
36
92
277
3035
5
11
308
3116
—
22
14
288
3104
47
103
239
2901
43
279
140
2081
Extensive abdominal CT
JN3BD [2001305556]
8.4e-01
2.3e+00
—
—
—
2.5e+00
1.8e+00
cases:2.56%
controls:1.12%
cases:2.56%
controls:0.26%
—
—
—
—
—
—
cases:3.15%
controls:0.27%
cases:6.56%
controls:1.10%
8
35
305
3092
8
8
305
3119
—
—
—
9
8
277
2996
12
26
171
2334
Emergency Room Visit
ER [9203]
2.8e-01
1.2e+00
1.8e+00
—
1.6e+00
1.3e+00
7.1e-01
cases:46.96%
controls:40.13%
cases:31.63%
controls:12.66%
cases:8.63%
controls:1.50%
—
—
cases:8.06%
controls:1.70%
cases:34.27%
controls:12.15%
cases:50.27%
controls:33.14%
147
1255
166
1872
99
396
214
2731
27
47
286
3080
—
25
53
285
3065
98
365
188
2639
92
782
91
1578
dexamethasone; oral, parenteral
H02AB02 [21602730]
5.9e-01
—
-1.0e+50
—
2.7e+00
2.3e+00
1.5e+00
cases:2.56%
controls:1.44%
—
—
cases:0.00%
controls:0.19%
—
—
cases:2.26%
controls:0.16%
cases:8.04%
controls:0.83%
cases:10.93%
controls:2.58%
8
45
305
3082
—
0
6
313
3121
—
7
5
303
3113
23
25
263
2979
20
61
163
2299
Gas panel - Venous blood
24339-4 [3000991]
7.7e-01
2.0e+00
—
—
2.9e+00
1.5e+00
7.2e-01
cases:3.19%
controls:1.50%
cases:6.39%
controls:0.90%
—
—
—
—
cases:2.90%
controls:0.16%
cases:5.24%
controls:1.17%
cases:8.20%
controls:4.15%
10
47
303
3080
20
28
293
3099
—
—
9
5
301
3113
15
35
271
2969
15
98
168
2262
Other and unspecified hydronephrosis
N13.3 [45553432]
2.3e+00
4.2e+00
1.0e+50
1.0e+50
1.0e+50
—
—
cases:2.88%
controls:0.29%
cases:9.27%
controls:0.16%
cases:7.99%
controls:0.00%
cases:5.75%
controls:0.00%
cases:4.84%
controls:0.00%
—
—
—
—
9
9
304
3118
29
5
284
3122
25
0
288
3127
18
0
295
3127
15
0
295
3118
—
—
Urinary tract infection, site not specified
N39.0 [45548665]
1.2e+00
2.0e+00
—
—
—
2.1e+00
1.2e+00
cases:7.35%
controls:2.43%
cases:5.43%
controls:0.80%
—
—
—
—
—
—
cases:5.94%
controls:0.77%
cases:12.02%
controls:3.77%
23
76
290
3051
17
25
296
3102
—
—
—
17
23
269
2981
22
89
161
2271
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
3.9e-01
7.3e-01
1.8e+00
—
1.6e+00
1.2e+00
9.9e-01
cases:30.99%
controls:23.31%
cases:23.64%
controls:12.95%
cases:7.67%
controls:1.41%
—
—
cases:9.35%
controls:1.99%
cases:34.97%
controls:13.35%
cases:55.74%
controls:31.78%
97
729
216
2398
74
405
239
2722
24
44
289
3083
—
29
62
281
3056
100
401
186
2603
102
750
81
1610
Immunohistochemistry procedure
117617002 [4035726]
1.9e+00
2.0e+00
—
—
1.0e+50
—
2.4e+00
cases:3.83%
controls:0.58%
cases:1.92%
controls:0.26%
—
—
—
—
cases:1.94%
controls:0.00%
—
—
cases:8.20%
controls:0.81%
12
18
301
3109
6
8
307
3119
—
—
6
0
304
3118
—
15
19
168
2341
Kidney ultrasound examination
KA1AE [2001305627]
3.0e+00
—
—
—
—
1.0e+50
3.2e+00
cases:3.19%
controls:0.16%
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.00%
cases:6.01%
controls:0.25%
10
5
303
3122
—
—
—
—
7
0
279
3004
11
6
172
2354
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
3.7e-01
9.8e-01
1.2e+00
—
1.9e+00
1.1e+00
9.6e-01
cases:18.53%
controls:13.53%
cases:18.21%
controls:7.74%
cases:4.79%
controls:1.47%
—
—
cases:8.39%
controls:1.31%
cases:20.98%
controls:7.89%
cases:39.89%
controls:20.21%
58
423
255
2704
57
242
256
2885
15
46
298
3081
—
26
41
284
3077
60
237
226
2767
73
477
110
1883
oxycodone; oral, parenteral
N02AA05 [21604260]
5.2e-01
9.3e-01
—
—
2.5e+00
2.3e+00
1.4e+00
cases:2.56%
controls:1.54%
cases:2.56%
controls:1.02%
—
—
—
—
cases:2.90%
controls:0.26%
cases:10.14%
controls:1.10%
cases:15.85%
controls:4.36%
8
48
305
3079
8
32
305
3095
—
—
9
8
301
3110
29
33
257
2971
29
103
154
2257
cefalexin; oral
J01DB01 [21602870]
5.4e-01
6.9e-01
1.3e+00
—
1.7e+00
1.1e+00
7.4e-01
cases:38.98%
controls:27.21%
cases:16.29%
controls:8.86%
cases:3.51%
controls:0.96%
—
—
cases:4.84%
controls:0.90%
cases:21.68%
controls:8.09%
cases:42.08%
controls:25.68%
122
851
191
2276
51
277
262
2850
11
30
302
3097
—
15
28
295
3090
62
243
224
2761
77
606
106
1754
Emergency Room and Inpatient Visit
ERIP [262]
4.0e-01
1.1e+00
1.8e+00
1.0e+50
1.9e+00
1.4e+00
4.8e-01
cases:9.58%
controls:6.65%
cases:11.82%
controls:4.48%
cases:4.15%
controls:0.74%
cases:2.88%
controls:0.00%
cases:4.19%
controls:0.64%
cases:17.48%
controls:4.86%
cases:25.14%
controls:17.16%
30
208
283
2919
37
140
276
2987
13
23
300
3104
9
0
304
3127
13
20
297
3098
50
146
236
2858
46
405
137
1955
Ultrasound measurement of residual urine
KC1EE [2001305918]
1.1e+00
1.8e+00
—
—
—
2.0e+00
1.3e+00
cases:8.95%
controls:3.26%
cases:5.75%
controls:0.99%
—
—
—
—
—
—
cases:6.99%
controls:1.03%
cases:12.02%
controls:3.64%
28
102
285
3025
18
31
295
3096
—
—
—
20
31
266
2973
22
86
161
2274
Essential (primary) hypertension
I10 [45591453]
2.0e-01
3.8e-01
7.8e-01
4.1e+00
1.1e+00
8.8e-01
1.9e-01
cases:35.78%
controls:31.40%
cases:22.04%
controls:16.21%
cases:5.43%
controls:2.56%
cases:10.54%
controls:0.19%
cases:7.74%
controls:2.69%
cases:31.47%
controls:16.05%
cases:44.26%
controls:39.75%
112
982
201
2145
69
507
244
2620
17
80
296
3047
33
6
280
3121
24
84
286
3034
90
482
196
2522
81
938
102
1422
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.4e-02
2.6e-01
1.6e+00
2.6e+00
1.9e+00
2.6e-01
-2.4e-02
cases:36.74%
controls:36.42%
cases:34.19%
controls:28.59%
cases:21.41%
controls:5.34%
cases:5.43%
controls:0.42%
cases:26.45%
controls:5.26%
cases:36.01%
controls:30.23%
cases:48.09%
controls:48.69%
115
1139
198
1988
107
894
206
2233
67
167
246
2960
17
13
296
3114
82
164
228
2954
103
908
183
2096
88
1149
95
1211
Abdominal CT examination
JN3AD [2001305554]
1.1e+00
2.0e+00
—
—
—
2.7e+00
1.3e+00
cases:3.51%
controls:1.18%
cases:3.83%
controls:0.54%
—
—
—
—
—
—
cases:8.39%
controls:0.63%
cases:10.93%
controls:3.09%
11
37
302
3090
12
17
301
3110
—
—
—
24
19
262
2985
20
73
163
2287
pH of Serum or Plasma
2753-2 [3018418]
3.8e-01
4.5e-01
2.0e+00
—
2.1e+00
1.1e+00
7.8e-01
cases:10.22%
controls:7.23%
cases:6.71%
controls:4.38%
cases:2.24%
controls:0.32%
—
—
cases:4.19%
controls:0.51%
cases:11.19%
controls:3.99%
cases:20.77%
controls:10.76%
32
226
281
2901
21
137
292
2990
7
10
306
3117
—
13
16
297
3102
32
120
254
2884
38
254
145
2106
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
-3.3e-01
9.4e-01
—
—
2.8e+00
1.9e+00
1.2e+00
cases:2.24%
controls:3.07%
cases:3.83%
controls:1.54%
—
—
—
—
cases:3.23%
controls:0.19%
cases:8.74%
controls:1.36%
cases:12.57%
controls:4.15%
7
96
306
3031
12
48
301
3079
—
—
10
6
300
3112
25
41
261
2963
23
98
160
2262
Systemic arterial pressure
364090009 [4238447]
—
—
—
1.0e+50
—
3.3e+00
2.7e+00
—
—
—
—
—
—
cases:1.60%
controls:0.00%
—
—
cases:4.20%
controls:0.17%
cases:5.46%
controls:0.38%
—
—
—
5
0
308
3127
—
12
5
274
2999
10
9
173
2351
Cathetrisation of vein
TPH04 [2001309597]
9.8e-01
1.5e+00
—
1.0e+50
1.9e+00
1.8e+00
1.6e+00
cases:8.63%
controls:3.42%
cases:4.79%
controls:1.09%
—
—
cases:2.56%
controls:0.00%
cases:1.61%
controls:0.26%
cases:6.64%
controls:1.13%
cases:15.30%
controls:3.43%
27
107
286
3020
15
34
298
3093
—
8
0
305
3127
5
8
305
3110
19
34
267
2970
28
81
155
2279
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
5.2e-01
9.3e-01
1.5e+00
—
2.4e+00
9.5e-01
5.4e-01
cases:18.53%
controls:11.96%
cases:14.38%
controls:6.24%
cases:3.51%
controls:0.80%
—
—
cases:8.06%
controls:0.77%
cases:15.38%
controls:6.56%
cases:27.32%
controls:17.92%
58
374
255
2753
45
195
268
2932
11
25
302
3102
—
25
24
285
3094
44
197
242
2807
50
423
133
1937
Uroflowmetry
44856007 [4261340]
7.5e-01
1.9e+00
—
—
—
1.7e+00
1.4e+00
cases:8.63%
controls:4.25%
cases:7.35%
controls:1.22%
—
—
—
—
—
—
cases:7.34%
controls:1.36%
cases:14.21%
controls:3.77%
27
133
286
2994
23
38
290
3089
—
—
—
21
41
265
2963
26
89
157
2271
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
6.3e-01
8.5e-01
3.2e+00
—
—
1.4e+00
9.7e-01
cases:4.47%
controls:2.43%
cases:4.15%
controls:1.82%
cases:3.83%
controls:0.16%
—
—
—
—
cases:4.90%
controls:1.20%
cases:9.29%
controls:3.73%
14
76
299
3051
13
57
300
3070
12
5
301
3122
—
—
14
36
272
2968
17
88
166
2272
EKG study
11524-6 [3013512]
3.0e-01
5.2e-01
2.6e+00
—
2.1e+00
8.7e-01
2.6e-01
cases:15.02%
controls:11.54%
cases:12.46%
controls:7.80%
cases:7.99%
controls:0.67%
—
—
cases:5.16%
controls:0.64%
cases:15.73%
controls:7.22%
cases:21.86%
controls:17.80%
47
361
266
2766
39
244
274
2883
25
21
288
3106
—
16
20
294
3098
45
217
241
2787
40
420
143
1940
More than three and less than five hours
ZXE20 [2001311408]
8.0e-01
1.8e+00
—
1.0e+50
—
3.6e+00
1.9e+00
cases:3.83%
controls:1.76%
cases:1.92%
controls:0.32%
—
—
cases:1.92%
controls:0.00%
—
—
cases:5.59%
controls:0.17%
cases:4.37%
controls:0.68%
12
55
301
3072
6
10
307
3117
—
6
0
307
3127
—
16
5
270
2999
8
16
175
2344
Cells panel - Urine sediment
58434-2 [40761535]
5.0e-01
1.2e+00
2.5e+00
—
—
1.7e+00
1.3e+00
cases:4.47%
controls:2.75%
cases:3.83%
controls:1.22%
cases:2.24%
controls:0.19%
—
—
—
—
cases:5.59%
controls:1.07%
cases:9.84%
controls:2.92%
14
86
299
3041
12
38
301
3089
7
6
306
3121
—
—
16
32
270
2972
18
69
165
2291
Supplier / Service Provider
OMOP5117446 [33004]
-2.3e-01
2.8e-01
1.1e+00
—
—
2.6e+00
2.8e+00
cases:19.49%
controls:23.35%
cases:7.67%
controls:5.92%
cases:1.92%
controls:0.67%
—
—
—
—
cases:12.24%
controls:1.03%
cases:22.95%
controls:1.69%
61
730
252
2397
24
185
289
2942
6
21
307
3106
—
—
35
31
251
2973
42
40
141
2320
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
8.2e-01
1.1e+00
—
—
2.4e+00
1.8e+00
1.2e+00
cases:4.79%
controls:2.17%
cases:3.83%
controls:1.25%
—
—
—
—
cases:3.55%
controls:0.32%
cases:6.99%
controls:1.26%
cases:11.48%
controls:3.64%
15
68
298
3059
12
39
301
3088
—
—
11
10
299
3108
20
38
266
2966
21
86
162
2274
Pure hypercholesterolaemia
E78.01 [2000501514]
6.6e-01
1.3e+00
2.8e+00
1.0e+50
1.3e+00
1.3e+00
5.9e-01
cases:8.95%
controls:4.83%
cases:7.99%
controls:2.27%
cases:2.56%
controls:0.16%
cases:4.47%
controls:0.00%
cases:1.94%
controls:0.55%
cases:9.44%
controls:2.76%
cases:15.30%
controls:9.11%
28
151
285
2976
25
71
288
3056
8
5
305
3122
14
0
299
3127
6
17
304
3101
27
83
259
2921
28
215
155
2145
Extensive body CT
JN4BD [2001310899]
1.9e+00
—
—
—
—
—
3.5e+00
cases:3.83%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:10.38%
controls:0.34%
12
19
301
3108
—
—
—
—
—
19
8
164
2352
sulfadiazine and trimethoprim
J01EE02 [21602962]
6.4e-01
2.0e+00
—
—
—
1.8e+00
1.5e+00
cases:4.79%
controls:2.59%
cases:3.19%
controls:0.45%
—
—
—
—
—
—
cases:3.85%
controls:0.63%
cases:10.38%
controls:2.50%
15
81
298
3046
10
14
303
3113
—
—
—
11
19
275
2985
19
59
164
2301
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
2.5e-01
9.1e-01
2.3e+00
—
—
1.3e+00
7.6e-01
cases:10.22%
controls:8.12%
cases:8.63%
controls:3.68%
cases:2.56%
controls:0.26%
—
—
—
—
cases:11.54%
controls:3.30%
cases:19.13%
controls:10.00%
32
254
281
2873
27
115
286
3012
8
8
305
3119
—
—
33
99
253
2905
35
236
148
2124
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
-6.6e-02
8.6e-01
1.9e+00
—
1.6e+00
9.0e-01
5.6e-01
cases:6.07%
controls:6.46%
cases:7.67%
controls:3.39%
cases:3.51%
controls:0.54%
—
—
cases:2.90%
controls:0.58%
cases:9.44%
controls:4.06%
cases:19.13%
controls:11.86%
19
202
294
2925
24
106
289
3021
11
17
302
3110
—
9
18
301
3100
27
122
259
2882
35
280
148
2080
Emergency Medicine
93 [38004510]
2.2e-01
8.1e-01
1.7e+00
—
1.7e+00
1.1e+00
3.8e-01
cases:22.36%
controls:18.77%
cases:21.41%
controls:10.81%
cases:7.35%
controls:1.44%
—
—
cases:7.42%
controls:1.51%
cases:27.97%
controls:11.28%
cases:39.34%
controls:30.72%
70
587
243
2540
67
338
246
2789
23
45
290
3082
—
23
47
287
3071
80
339
206
2665
72
725
111
1635
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
2.6e+00
2.6e+00
—
1.0e+50
1.0e+50
—
—
cases:2.56%
controls:0.19%
cases:2.56%
controls:0.19%
—
—
cases:1.92%
controls:0.00%
cases:3.23%
controls:0.00%
—
—
—
—
8
6
305
3121
8
6
305
3121
—
6
0
307
3127
10
0
300
3118
—
—
Right side
ZXA00 [2001311346]
3.4e-01
7.0e-01
—
1.0e+50
2.3e+00
1.6e+00
1.2e+00
cases:7.67%
controls:5.60%
cases:2.56%
controls:1.28%
—
—
cases:1.92%
controls:0.00%
cases:2.26%
controls:0.22%
cases:5.59%
controls:1.23%
cases:8.74%
controls:2.71%
24
175
289
2952
8
40
305
3087
—
6
0
307
3127
7
7
303
3111
16
37
270
2967
16
64
167
2296
tranexamic acid; oral, parenteral
B02AA02 [21601036]
2.3e+00
—
—
—
—
—
2.8e+00
cases:2.24%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
cases:3.28%
controls:0.21%
7
7
306
3120
—
—
—
—
—
6
5
177
2355
Palliative care
Z51.5 [45547323]
—
—
—
—
—
2.7e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.33%
cases:8.74%
controls:0.93%
—
—
—
—
—
13
10
273
2994
16
22
167
2338
enoxaparin; parenteral
B01AB05 [21600976]
5.9e-01
1.4e+00
2.3e+00
—
—
2.6e+00
9.5e-01
cases:9.90%
controls:5.72%
cases:6.71%
controls:1.66%
cases:1.60%
controls:0.16%
—
—
—
—
cases:18.18%
controls:1.70%
cases:12.02%
controls:5.00%
31
179
282
2948
21
52
292
3075
5
5
308
3122
—
—
52
51
234
2953
22
118
161
2242
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
8.6e-01
2.0e+00
—
—
—
1.7e+00
1.2e+00
cases:2.24%
controls:0.96%
cases:3.51%
controls:0.48%
—
—
—
—
—
—
cases:3.15%
controls:0.57%
cases:8.20%
controls:2.67%
7
30
306
3097
11
15
302
3112
—
—
—
9
17
277
2987
15
63
168
2297
Specific gravity of Urine by Refractometry
5810-7 [3019150]
-1.9e-01
1.0e+00
2.2e+00
—
1.6e+00
6.7e-01
4.6e-01
cases:6.39%
controls:7.64%
cases:9.27%
controls:3.52%
cases:4.47%
controls:0.51%
—
—
cases:2.58%
controls:0.51%
cases:7.69%
controls:4.09%
cases:16.39%
controls:10.97%
20
239
293
2888
29
110
284
3017
14
16
299
3111
—
8
16
302
3102
22
123
264
2881
30
259
153
2101
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
1.2e+00
—
—
—
—
3.2e+00
1.6e+00
cases:2.24%
controls:0.70%
—
—
—
—
—
—
—
—
cases:4.90%
controls:0.20%
cases:4.37%
controls:0.89%
7
22
306
3105
—
—
—
—
14
6
272
2998
8
21
175
2339
Acute cystitis
N30.0 [45601724]
8.2e-01
1.9e+00
—
—
—
1.7e+00
1.2e+00
cases:4.47%
controls:2.01%
cases:4.47%
controls:0.70%
—
—
—
—
—
—
cases:4.55%
controls:0.87%
cases:11.48%
controls:3.60%
14
63
299
3064
14
22
299
3105
—
—
—
13
26
273
2978
21
85
162
2275
More than five and less than seven hours
ZXE30 [2001311411]
1.7e+00
—
—
—
—
—
2.9e+00
cases:2.56%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:3.83%
controls:0.21%
8
15
305
3112
—
—
—
—
—
7
5
176
2355
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2.0e-01
4.5e-01
—
—
2.7e+00
1.2e+00
7.6e-01
cases:8.95%
controls:7.42%
cases:4.79%
controls:3.10%
—
—
—
—
cases:2.26%
controls:0.16%
cases:10.49%
controls:3.50%
cases:21.86%
controls:11.57%
28
232
285
2895
15
97
298
3030
—
—
7
5
303
3113
30
105
256
2899
40
273
143
2087
Case Management Agency
251B00000X [38004193]
-4.2e-03
3.9e-01
8.6e-01
3.0e+00
7.3e-01
2.8e-01
-1.2e-01
cases:77.00%
controls:77.07%
cases:77.00%
controls:69.40%
cases:47.92%
controls:28.11%
cases:27.80%
controls:1.95%
cases:45.48%
controls:28.64%
cases:77.27%
controls:71.94%
cases:87.98%
controls:89.15%
241
2410
72
717
241
2170
72
957
150
879
163
2248
87
61
226
3066
141
893
169
2225
221
2161
65
843
161
2104
22
256
ABO and Rh group [Type] in Blood
882-1 [3003694]
5.3e-01
1.8e+00
—
—
2.7e+00
6.5e-01
-2.1e-01
cases:8.31%
controls:5.05%
cases:7.99%
controls:1.41%
—
—
—
—
cases:2.90%
controls:0.19%
cases:2.45%
controls:1.30%
cases:4.92%
controls:6.02%
26
158
287
2969
25
44
288
3083
—
—
9
6
301
3112
7
39
279
2965
9
142
174
2218
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
2.1e+00
—
—
—
—
—
2.4e+00
cases:3.19%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:2.73%
controls:0.25%
10
12
303
3115
—
—
—
—
—
5
6
178
2354
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
1.2e+00
2.2e+00
—
1.0e+50
—
2.3e+00
9.0e-01
cases:2.88%
controls:0.90%
cases:2.88%
controls:0.32%
—
—
cases:2.56%
controls:0.00%
—
—
cases:4.90%
controls:0.53%
cases:4.37%
controls:1.82%
9
28
304
3099
9
10
304
3117
—
8
0
305
3127
—
14
16
272
2988
8
43
175
2317
12 lead EKG panel
34534-8 [3044889]
2.0e-01
7.3e-01
1.8e+00
—
1.9e+00
5.0e-01
2.1e-01
cases:30.99%
controls:26.80%
cases:25.88%
controls:14.42%
cases:10.86%
controls:1.95%
—
—
cases:9.03%
controls:1.48%
cases:21.33%
controls:14.11%
cases:39.34%
controls:34.36%
97
838
216
2289
81
451
232
2676
34
61
279
3066
—
28
46
282
3072
61
424
225
2580
72
811
111
1549
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
—
—
—
—
—
2.7e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:2.80%
controls:0.20%
cases:4.92%
controls:0.89%
—
—
—
—
—
8
6
278
2998
9
21
174
2339
Laceration/cut
S18 [2002000983]
6.2e-01
2.5e-01
—
—
2.2e+00
1.2e+00
5.2e-01
cases:18.21%
controls:10.71%
cases:5.43%
controls:4.29%
—
—
—
—
cases:4.19%
controls:0.48%
cases:13.99%
controls:4.53%
cases:20.77%
controls:13.43%
57
335
256
2792
17
134
296
2993
—
—
13
15
297
3103
40
136
246
2868
38
317
145
2043
Normoblasts [#/volume] in Blood
715-3 [3021589]
3.5e-01
5.3e-01
1.7e+00
—
1.6e+00
7.3e-01
4.8e-01
cases:14.06%
controls:10.33%
cases:14.70%
controls:9.24%
cases:9.27%
controls:1.92%
—
—
cases:9.03%
controls:1.99%
cases:17.83%
controls:9.49%
cases:28.96%
controls:20.13%
44
323
269
2804
46
289
267
2838
29
60
284
3067
—
28
62
282
3056
51
285
235
2719
53
475
130
1885
Nephrology
39 [38004479]
9.6e-01
1.2e+00
1.7e+00
—
2.0e+00
1.9e+00
9.2e-01
cases:4.15%
controls:1.63%
cases:3.83%
controls:1.18%
cases:1.92%
controls:0.35%
—
—
cases:2.58%
controls:0.35%
cases:7.34%
controls:1.17%
cases:5.46%
controls:2.25%
13
51
300
3076
12
37
301
3090
6
11
307
3116
—
8
11
302
3107
21
35
265
2969
10
53
173
2307
Base excess in Arterial blood by calculation
1925-7 [3003396]
9.8e-01
1.2e+00
-1.0e+50
—
—
1.7e+00
4.8e-01
cases:5.11%
controls:1.98%
cases:3.83%
controls:1.15%
cases:0.00%
controls:0.26%
—
—
—
—
cases:5.94%
controls:1.17%
cases:6.56%
controls:4.15%
16
62
297
3065
12
36
301
3091
0
8
313
3119
—
—
17
35
269
2969
12
98
171
2262
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
4.8e-01
1.4e+00
—
—
—
1.4e+00
1.1e+00
cases:2.56%
controls:1.60%
cases:3.51%
controls:0.90%
—
—
—
—
—
—
cases:3.50%
controls:0.90%
cases:8.74%
controls:3.09%
8
50
305
3077
11
28
302
3099
—
—
—
10
27
276
2977
16
73
167
2287
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
1.6e-01
1.2e+00
—
—
—
1.4e+00
1.2e+00
cases:4.15%
controls:3.55%
cases:4.15%
controls:1.25%
—
—
—
—
—
—
cases:5.59%
controls:1.46%
cases:12.02%
controls:4.03%
13
111
300
3016
13
39
300
3088
—
—
—
16
44
270
2960
22
95
161
2265
nitrofurantoin; oral
J01XE01 [21603058]
5.6e-01
8.5e-01
—
—
—
2.6e+00
1.2e+00
cases:4.79%
controls:2.78%
cases:1.92%
controls:0.83%
—
—
—
—
—
—
cases:9.44%
controls:0.80%
cases:9.29%
controls:3.01%
15
87
298
3040
6
26
307
3101
—
—
—
27
24
259
2980
17
71
166
2289
Protein [Mass/volume] in Urine
2888-6 [3037121]
1.6e+00
2.0e+00
—
—
—
—
—
cases:3.83%
controls:0.83%
cases:1.92%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
12
26
301
3101
6
8
307
3119
—
—
—
—
—
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
1.0e+00
2.0e+00
—
1.0e+50
1.0e+50
1.6e+00
3.3e-01
cases:2.24%
controls:0.83%
cases:3.19%
controls:0.45%
—
—
cases:1.92%
controls:0.00%
cases:2.58%
controls:0.00%
cases:3.15%
controls:0.67%
cases:3.28%
controls:2.37%
7
26
306
3101
10
14
303
3113
—
6
0
307
3127
8
0
302
3118
9
20
277
2984
6
56
177
2304
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.4e-01
4.9e-01
5.0e-01
—
1.4e+00
1.0e+00
6.8e-01
cases:49.84%
controls:41.38%
cases:35.46%
controls:25.14%
cases:9.27%
controls:5.82%
—
—
cases:18.71%
controls:5.58%
cases:48.60%
controls:25.23%
cases:66.12%
controls:49.75%
156
1294
157
1833
111
786
202
2341
29
182
284
2945
—
58
174
252
2944
139
758
147
2246
121
1174
62
1186
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
1.3e+00
1.6e+00
-1.0e+50
—
1.0e+50
1.9e+00
6.3e-01
cases:2.24%
controls:0.64%
cases:2.88%
controls:0.58%
cases:0.00%
controls:0.16%
—
—
cases:3.23%
controls:0.00%
cases:3.50%
controls:0.53%
cases:4.37%
controls:2.37%
7
20
306
3107
9
18
304
3109
0
5
313
3122
—
10
0
300
3118
10
16
276
2988
8
56
175
2304
Respiratory and circulatory monitoring
WX700 [2001310817]
5.5e-01
1.3e+00
—
1.0e+50
—
2.0e+00
1.4e+00
cases:4.15%
controls:2.43%
cases:2.88%
controls:0.83%
—
—
cases:2.88%
controls:0.00%
—
—
cases:4.20%
controls:0.57%
cases:7.65%
controls:2.03%
13
76
300
3051
9
26
304
3101
—
9
0
304
3127
—
12
17
274
2987
14
48
169
2312
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
1.0e+00
1.5e+00
—
1.0e+50
—
1.8e+00
5.9e-01
cases:3.83%
controls:1.44%
cases:3.51%
controls:0.77%
—
—
cases:3.19%
controls:0.00%
—
—
cases:5.59%
controls:0.93%
cases:6.01%
controls:3.43%
12
45
301
3082
11
24
302
3103
—
10
0
303
3127
—
16
28
270
2976
11
81
172
2279
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
1.0e+00
1.9e+00
-1.0e+50
—
1.0e+50
1.5e+00
2.4e-01
cases:2.24%
controls:0.80%
cases:3.19%
controls:0.51%
cases:0.00%
controls:0.16%
—
—
cases:2.58%
controls:0.00%
cases:3.15%
controls:0.73%
cases:3.28%
controls:2.58%
7
25
306
3102
10
16
303
3111
0
5
313
3122
—
8
0
302
3118
9
22
277
2982
6
61
177
2299
Oxygen saturation in Arterial blood
2708-6 [3016502]
9.2e-01
1.5e+00
—
—
—
1.8e+00
3.8e-01
cases:4.15%
controls:1.69%
cases:3.83%
controls:0.90%
—
—
—
—
—
—
cases:6.29%
controls:1.07%
cases:5.46%
controls:3.81%
13
53
300
3074
12
28
301
3099
—
—
—
18
32
268
2972
10
90
173
2270
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.9e-01
9.3e-01
—
—
2.2e+00
1.3e+00
1.1e+00
cases:3.51%
controls:2.91%
cases:2.88%
controls:1.15%
—
—
—
—
cases:1.94%
controls:0.22%
cases:3.50%
controls:0.93%
cases:9.29%
controls:3.39%
11
91
302
3036
9
36
304
3091
—
—
6
7
304
3111
10
28
276
2976
17
80
166
2280
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
8.0e-01
1.4e+00
—
—
—
1.9e+00
1.3e+00
cases:7.03%
controls:3.29%
cases:2.56%
controls:0.64%
—
—
—
—
—
—
cases:5.94%
controls:0.93%
cases:12.57%
controls:3.73%
22
103
291
3024
8
20
305
3107
—
—
—
17
28
269
2976
23
88
160
2272
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
—
—
—
—
—
1.8e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:2.80%
controls:0.47%
cases:5.46%
controls:1.44%
—
—
—
—
—
8
14
278
2990
10
34
173
2326
Thoracal epidural anesthesia
WX302 [2001310795]
—
—
—
1.0e+50
1.0e+50
1.0e+50
3.2e+00
—
—
—
—
—
—
cases:2.56%
controls:0.00%
cases:3.23%
controls:0.00%
cases:7.69%
controls:0.00%
cases:6.56%
controls:0.30%
—
—
—
8
0
305
3127
10
0
300
3118
22
0
264
3004
12
7
171
2353
pH of Arterial blood
2744-1 [3019977]
9.1e-01
1.3e+00
—
—
—
1.9e+00
4.7e-01
cases:4.79%
controls:1.98%
cases:4.15%
controls:1.22%
—
—
—
—
—
—
cases:6.99%
controls:1.17%
cases:6.56%
controls:4.19%
15
62
298
3065
13
38
300
3089
—
—
—
20
35
266
2969
12
99
171
2261
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
1.1e+00
1.3e+00
—
—
—
1.6e+00
1.5e+00
cases:3.83%
controls:1.34%
cases:3.19%
controls:0.90%
—
—
—
—
—
—
cases:3.50%
controls:0.70%
cases:7.10%
controls:1.74%
12
42
301
3085
10
28
303
3099
—
—
—
10
21
276
2983
13
41
170
2319
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
9.5e-01
1.3e+00
—
—
—
1.7e+00
5.6e-01
cases:5.11%
controls:2.05%
cases:4.15%
controls:1.18%
—
—
—
—
—
—
cases:6.64%
controls:1.23%
cases:7.10%
controls:4.19%
16
64
297
3063
13
37
300
3090
—
—
—
19
37
267
2967
13
99
170
2261
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
9.6e-01
1.3e+00
—
—
—
1.7e+00
5.6e-01
cases:5.11%
controls:2.01%
cases:4.15%
controls:1.18%
—
—
—
—
—
—
cases:6.64%
controls:1.23%
cases:7.10%
controls:4.19%
16
63
297
3064
13
37
300
3090
—
—
—
19
37
267
2967
13
99
170
2261
pH of Capillary blood
2745-8 [3009343]
6.6e-01
—
—
—
—
1.8e+00
1.2e+00
cases:2.88%
controls:1.50%
—
—
—
—
—
—
—
—
cases:5.59%
controls:0.97%
cases:8.20%
controls:2.58%
9
47
304
3080
—
—
—
—
16
29
270
2975
15
61
168
2299
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
6.6e-01
—
—
—
—
1.8e+00
1.2e+00
cases:2.88%
controls:1.50%
—
—
—
—
—
—
—
—
cases:5.94%
controls:1.03%
cases:8.20%
controls:2.63%
9
47
304
3080
—
—
—
—
17
31
269
2973
15
62
168
2298
Chronic kidney disease, unspecified
N18.9 [45553438]
4.3e-01
1.5e+00
—
—
—
1.5e+00
1.1e+00
cases:2.24%
controls:1.47%
cases:4.15%
controls:0.99%
—
—
—
—
—
—
cases:4.90%
controls:1.10%
cases:7.10%
controls:2.58%
7
46
306
3081
13
31
300
3096
—
—
—
14
33
272
2971
13
61
170
2299
pH of Venous blood
2746-6 [3012544]
5.9e-01
1.6e+00
—
—
—
1.4e+00
6.9e-01
cases:4.15%
controls:2.33%
cases:5.75%
controls:1.22%
—
—
—
—
—
—
cases:5.59%
controls:1.50%
cases:10.38%
controls:5.51%
13
73
300
3054
18
38
295
3089
—
—
—
16
45
270
2959
19
130
164
2230
General Practice
1 [38004446]
6.1e-02
6.1e-01
1.0e+00
—
1.4e+00
8.9e-01
4.6e-01
cases:19.49%
controls:18.55%
cases:15.02%
controls:8.73%
cases:2.56%
controls:0.96%
—
—
cases:4.84%
controls:1.19%
cases:20.28%
controls:9.42%
cases:34.97%
controls:25.38%
61
580
252
2547
47
273
266
2854
8
30
305
3097
—
15
37
295
3081
58
283
228
2721
64
599
119
1761
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
4.4e-01
1.6e+00
1.7e+00
—
—
1.3e+00
7.5e-01
cases:3.51%
controls:2.30%
cases:5.75%
controls:1.22%
cases:1.60%
controls:0.29%
—
—
—
—
cases:5.94%
controls:1.63%
cases:10.93%
controls:5.47%
11
72
302
3055
18
38
295
3089
5
9
308
3118
—
—
17
49
269
2955
20
129
163
2231
Short blood count panel - Blood
55429-5 [40758558]
3.2e-01
7.7e-01
1.3e+00
—
2.2e+00
8.0e-01
7.3e-01
cases:7.35%
controls:5.44%
cases:5.43%
controls:2.59%
cases:1.92%
controls:0.54%
—
—
cases:3.87%
controls:0.45%
cases:5.94%
controls:2.76%
cases:16.94%
controls:8.94%
23
170
290
2957
17
81
296
3046
6
17
307
3110
—
12
14
298
3104
17
83
269
2921
31
211
152
2149
oxycodone and naloxone; oral
N02AA55 [21604265]
-4.5e-01
—
—
—
2.1e+00
2.0e+00
9.1e-01
cases:1.92%
controls:2.97%
—
—
—
—
—
—
cases:1.61%
controls:0.19%
cases:7.34%
controls:1.10%
cases:10.38%
controls:4.45%
6
93
307
3034
—
—
—
5
6
305
3112
21
33
265
2971
19
105
164
2255
Cystoscopic insertion of stent into ureter
KBV02 [2001305891]
2.9e+00
—
1.0e+50
1.0e+50
1.0e+50
—
—
cases:4.79%
controls:0.29%
—
—
cases:1.60%
controls:0.00%
cases:6.39%
controls:0.00%
cases:2.26%
controls:0.00%
—
—
—
—
15
9
298
3118
—
5
0
308
3127
20
0
293
3127
7
0
303
3118
—
—
Base excess in Venous blood by calculation
1927-3 [3002032]
5.5e-01
1.6e+00
—
—
—
1.2e+00
7.4e-01
cases:3.83%
controls:2.24%
cases:5.75%
controls:1.22%
—
—
—
—
—
—
cases:5.24%
controls:1.56%
cases:10.38%
controls:5.25%
12
70
301
3057
18
38
295
3089
—
—
—
15
47
271
2957
19
124
164
2236
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
6.2e-01
8.5e-01
—
—
—
1.6e+00
1.2e+00
cases:2.88%
controls:1.57%
cases:1.92%
controls:0.83%
—
—
—
—
—
—
cases:3.15%
controls:0.63%
cases:8.20%
controls:2.71%
9
49
304
3078
6
26
307
3101
—
—
—
9
19
277
2985
15
64
168
2296
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
4.1e-01
1.6e+00
—
—
—
1.2e+00
3.2e-01
cases:3.19%
controls:2.14%
cases:4.79%
controls:1.06%
—
—
—
—
—
—
cases:4.20%
controls:1.26%
cases:6.01%
controls:4.45%
10
67
303
3060
15
33
298
3094
—
—
—
12
38
274
2966
11
105
172
2255
Infiltration anesthesia
WX110 [2001310767]
4.9e-01
5.1e-01
—
—
1.4e+00
8.7e-01
4.9e-02
cases:28.43%
controls:19.64%
cases:12.78%
controls:8.12%
—
—
—
—
cases:3.55%
controls:0.90%
cases:15.38%
controls:7.06%
cases:22.40%
controls:21.57%
89
614
224
2513
40
254
273
2873
—
—
11
28
299
3090
44
212
242
2792
41
509
142
1851
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
2.1e+00
—
—
—
1.0e+50
1.0e+50
2.7e+00
cases:1.60%
controls:0.19%
—
—
—
—
—
—
cases:1.61%
controls:0.00%
cases:4.20%
controls:0.00%
cases:6.01%
controls:0.42%
5
6
308
3121
—
—
—
5
0
305
3118
12
0
274
3004
11
10
172
2350
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.80%
controls:0.20%
—
—
—
—
—
—
—
8
6
278
2998
—
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
4.5e-01
5.5e-01
1.0e+00
—
1.3e+00
1.7e+00
9.4e-01
cases:12.46%
controls:8.28%
cases:4.15%
controls:2.43%
cases:1.92%
controls:0.70%
—
—
cases:2.90%
controls:0.77%
cases:11.89%
controls:2.40%
cases:15.30%
controls:6.57%
39
259
274
2868
13
76
300
3051
6
22
307
3105
—
9
24
301
3094
34
72
252
2932
28
155
155
2205
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.1e-01
8.6e-01
1.0e+00
—
6.3e-01
9.4e-01
8.1e-01
cases:14.06%
controls:10.68%
cases:13.42%
controls:6.14%
cases:3.19%
controls:1.15%
—
—
cases:2.26%
controls:1.22%
cases:14.69%
controls:6.32%
cases:30.05%
controls:16.10%
44
334
269
2793
42
192
271
2935
10
36
303
3091
—
7
38
303
3080
42
190
244
2814
55
380
128
1980
Other and unspecified ventral hernia without obstruction or gangrene
K43.9 [45533594]
1.3e+00
—
—
—
—
—
2.6e+00
cases:2.24%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:4.92%
controls:0.38%
7
19
306
3108
—
—
—
—
—
9
9
174
2351
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
3.0e-01
9.0e-01
1.0e+00
—
6.0e-01
9.3e-01
7.6e-01
cases:14.38%
controls:11.10%
cases:14.38%
controls:6.36%
cases:3.19%
controls:1.15%
—
—
cases:2.26%
controls:1.25%
cases:15.03%
controls:6.52%
cases:30.60%
controls:17.03%
45
347
268
2780
45
199
268
2928
10
36
303
3091
—
7
39
303
3079
43
196
243
2808
56
402
127
1958
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.1e-01
8.5e-01
1.0e+00
—
6.3e-01
9.2e-01
8.2e-01
cases:14.06%
controls:10.71%
cases:13.42%
controls:6.20%
cases:3.19%
controls:1.15%
—
—
cases:2.26%
controls:1.22%
cases:14.69%
controls:6.39%
cases:30.60%
controls:16.27%
44
335
269
2792
42
194
271
2933
10
36
303
3091
—
7
38
303
3080
42
192
244
2812
56
384
127
1976
darbepoetin alfa; parenteral
B03XA02 [21601134]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.73%
controls:0.21%
—
—
—
—
—
—
5
5
178
2355
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.1e-01
8.6e-01
1.0e+00
—
6.3e-01
9.3e-01
7.7e-01
cases:14.06%
controls:10.71%
cases:13.42%
controls:6.17%
cases:3.19%
controls:1.15%
—
—
cases:2.26%
controls:1.22%
cases:14.69%
controls:6.36%
cases:29.51%
controls:16.19%
44
335
269
2792
42
193
271
2934
10
36
303
3091
—
7
38
303
3080
42
191
244
2813
54
382
129
1978
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
2.3e-01
8.4e-01
1.1e+00
—
5.0e-01
9.0e-01
7.9e-01
cases:13.42%
controls:10.94%
cases:13.42%
controls:6.30%
cases:3.19%
controls:1.09%
—
—
cases:1.94%
controls:1.19%
cases:13.99%
controls:6.19%
cases:30.60%
controls:16.69%
42
342
271
2785
42
197
271
2930
10
34
303
3093
—
6
37
304
3081
40
186
246
2818
56
394
127
1966
Noninvasive ventilation
WX725 [2001310828]
1.3e+00
2.5e+00
—
1.0e+50
—
—
—
cases:1.60%
controls:0.45%
cases:1.92%
controls:0.16%
—
—
cases:1.60%
controls:0.00%
—
—
—
—
—
—
5
14
308
3113
6
5
307
3122
—
5
0
308
3127
—
—
—
Ultrasound examination of scrotum
KF8AE [2001306187]
2.5e+00
—
—
—
—
—
—
cases:2.24%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
7
6
306
3121
—
—
—
—
—
—
Removal of sutures
SPAT1153 [2001700254]
5.4e-01
3.0e-01
—
—
—
1.5e+00
9.7e-01
cases:12.14%
controls:7.42%
cases:2.24%
controls:1.66%
—
—
—
—
—
—
cases:6.29%
controls:1.50%
cases:12.02%
controls:4.92%
38
232
275
2895
7
52
306
3075
—
—
—
18
45
268
2959
22
116
161
2244
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
2.2e-01
9.6e-01
—
—
1.7e+00
1.5e+00
6.8e-01
cases:7.35%
controls:5.98%
cases:6.71%
controls:2.69%
—
—
—
—
cases:1.61%
controls:0.29%
cases:9.44%
controls:2.36%
cases:15.30%
controls:8.39%
23
187
290
2940
21
84
292
3043
—
—
5
9
305
3109
27
71
259
2933
28
198
155
2162
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.92%
controls:0.47%
—
—
—
—
—
—
9
11
174
2349
Intubation
WX704 [2001310820]
1.3e+00
2.0e+00
—
1.0e+50
1.0e+50
2.4e+00
8.9e-01
cases:2.56%
controls:0.70%
cases:1.60%
controls:0.22%
—
—
cases:2.24%
controls:0.00%
cases:1.94%
controls:0.00%
cases:2.10%
controls:0.20%
cases:2.73%
controls:1.14%
8
22
305
3105
5
7
308
3120
—
7
0
306
3127
6
0
304
3118
6
6
280
2998
5
27
178
2333
Office Visit
OMOP4822458 [581477]
4.9e-01
1.0e+00
—
—
—
1.4e+00
7.6e-02
cases:12.78%
controls:8.22%
cases:6.07%
controls:2.30%
—
—
—
—
—
—
cases:8.04%
controls:2.20%
cases:6.01%
controls:5.59%
40
257
273
2870
19
72
294
3055
—
—
—
23
66
263
2938
11
132
172
2228
Oxygen saturation in Capillary blood
2709-4 [3021901]
—
-1.0e+50
—
—
—
2.4e+00
1.5e+00
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
cases:1.75%
controls:0.17%
cases:3.83%
controls:0.89%
—
0
5
313
3122
—
—
—
5
5
281
2999
7
21
176
2339
Anion gap in Blood by calculation
41276-7 [3039000]
1.1e+00
—
—
—
—
2.4e+00
—
cases:1.60%
controls:0.51%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.17%
—
—
5
16
308
3111
—
—
—
—
5
5
281
2999
—
Chloride [Moles/volume] in Blood
2069-3 [3018572]
1.1e+00
—
—
—
—
2.4e+00
—
cases:1.60%
controls:0.51%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.17%
—
—
5
16
308
3111
—
—
—
—
5
5
281
2999
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
3.5e-01
7.9e-01
8.8e-01
—
4.7e-01
8.6e-01
6.8e-01
cases:15.02%
controls:11.06%
cases:13.74%
controls:6.72%
cases:2.88%
controls:1.22%
—
—
cases:1.94%
controls:1.22%
cases:14.34%
controls:6.62%
cases:30.60%
controls:18.26%
47
346
266
2781
43
210
270
2917
9
38
304
3089
—
6
38
304
3080
41
199
245
2805
56
431
127
1929
Other blockage of nerve
WX290 [2001310792]
3.8e-01
3.9e-01
—
1.0e+50
2.3e+00
8.2e-01
2.1e-01
cases:10.22%
controls:7.23%
cases:3.83%
controls:2.62%
—
—
cases:1.92%
controls:0.00%
cases:1.94%
controls:0.19%
cases:4.55%
controls:2.06%
cases:9.84%
controls:8.09%
32
226
281
2901
12
82
301
3045
—
6
0
307
3127
6
6
304
3112
13
62
273
2942
18
191
165
2169
Specific gravity of Urine by Test strip
5811-5 [3000330]
7.1e-01
9.3e-01
2.3e+00
—
—
—
-3.8e-01
cases:2.88%
controls:1.44%
cases:2.56%
controls:1.02%
cases:1.92%
controls:0.19%
—
—
—
—
—
—
cases:3.28%
controls:4.70%
9
45
304
3082
8
32
305
3095
6
6
307
3121
—
—
—
6
111
177
2249
Hypothyroidism, unspecified
E03.9 [45537945]
6.8e-01
1.0e+00
2.3e+00
—
—
6.6e-01
3.9e-01
cases:4.79%
controls:2.49%
cases:3.19%
controls:1.15%
cases:1.92%
controls:0.19%
—
—
—
—
cases:2.10%
controls:1.10%
cases:4.37%
controls:3.01%
15
78
298
3049
10
36
303
3091
6
6
307
3121
—
—
6
33
280
2971
8
71
175
2289
Basophils [#/volume] in Blood
26444-0 [3006315]
3.5e-01
7.9e-01
8.8e-01
—
4.7e-01
8.5e-01
6.7e-01
cases:15.02%
controls:11.10%
cases:13.74%
controls:6.75%
cases:2.88%
controls:1.22%
—
—
cases:1.94%
controls:1.22%
cases:14.34%
controls:6.66%
cases:30.60%
controls:18.35%
47
347
266
2780
43
211
270
2916
9
38
304
3089
—
6
38
304
3080
41
200
245
2804
56
433
127
1927
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
3.2e-01
8.3e-01
8.5e-01
—
4.2e-01
7.9e-01
6.6e-01
cases:15.65%
controls:11.90%
cases:14.70%
controls:7.00%
cases:2.88%
controls:1.25%
—
—
cases:1.94%
controls:1.28%
cases:13.99%
controls:6.86%
cases:31.15%
controls:18.98%
49
372
264
2755
46
219
267
2908
9
39
304
3088
—
6
40
304
3078
40
206
246
2798
57
448
126
1912
Bladder symptom/complaint other
U13 [2002001144]
1.5e+00
—
—
—
—
—
2.3e+00
cases:1.92%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:4.37%
controls:0.47%
6
13
307
3114
—
—
—
—
—
8
11
175
2349
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.3e-01
4.2e-01
9.3e-01
—
9.1e-01
4.0e-01
2.2e-01
cases:48.56%
controls:45.22%
cases:44.41%
controls:34.38%
cases:11.82%
controls:5.02%
—
—
cases:11.61%
controls:5.00%
cases:45.45%
controls:35.95%
cases:68.31%
controls:63.43%
152
1414
161
1713
139
1075
174
2052
37
157
276
2970
—
36
156
274
2962
130
1080
156
1924
125
1497
58
863
Haematuria
U06 [2002001141]
2.2e+00
—
—
—
—
—
1.7e+00
cases:3.51%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:3.28%
controls:0.64%
11
12
302
3115
—
—
—
—
—
6
15
177
2345
Glucose [Moles/volume] in Capillary blood
51596-5 [3040151]
—
-1.0e+50
—
—
—
—
2.2e+00
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
cases:2.73%
controls:0.30%
—
0
6
313
3121
—
—
—
—
5
7
178
2353
Eosinophils [#/volume] in Blood
26449-9 [3013115]
2.8e-01
7.3e-01
8.0e-01
—
4.4e-01
8.4e-01
6.6e-01
cases:15.02%
controls:11.80%
cases:13.74%
controls:7.10%
cases:2.88%
controls:1.31%
—
—
cases:1.94%
controls:1.25%
cases:14.34%
controls:6.76%
cases:31.15%
controls:18.90%
47
369
266
2758
43
222
270
2905
9
41
304
3086
—
6
39
304
3079
41
203
245
2801
57
446
126
1914
Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
83084-4 [42529201]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.10%
controls:0.23%
—
—
—
—
—
—
—
6
7
280
2997
—
Coloscopy
UJF32 [2001305029]
2.9e-02
1.1e+00
—
—
—
5.4e-01
1.1e+00
cases:4.47%
controls:4.35%
cases:4.47%
controls:1.47%
—
—
—
—
—
—
cases:2.10%
controls:1.23%
cases:13.11%
controls:4.96%
14
136
299
2991
14
46
299
3081
—
—
—
6
37
280
2967
24
117
159
2243
Urinary calculus, unspecified
N20.9 [45558141]
2.2e+00
—
—
—
—
—
—
cases:1.92%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
307
3120
—
—
—
—
—
—
Pulmonary embolism without mention of acute cor pulmonale
I26.9 [45552785]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.92%
controls:0.59%
—
—
—
—
—
—
9
14
174
2346
Internal Medicine
11 [38004456]
3.3e-01
6.2e-01
6.9e-01
—
7.8e-01
9.4e-01
5.9e-01
cases:35.14%
controls:28.01%
cases:17.89%
controls:10.46%
cases:3.19%
controls:1.63%
—
—
cases:3.23%
controls:1.51%
cases:22.03%
controls:9.95%
cases:35.52%
controls:23.43%
110
876
203
2251
56
327
257
2800
10
51
303
3076
—
10
47
300
3071
63
299
223
2705
65
553
118
1807
Lactate [Moles/volume] in Blood
32693-4 [3047181]
1.1e+00
—
—
—
—
2.1e+00
—
cases:2.56%
controls:0.83%
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.30%
—
—
8
26
305
3101
—
—
—
—
7
9
279
2995
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
8.2e-02
9.8e-01
7.1e-01
—
1.1e+00
1.4e-01
1.8e-01
cases:24.92%
controls:23.41%
cases:25.24%
controls:11.29%
cases:3.51%
controls:1.76%
—
—
cases:4.84%
controls:1.64%
cases:12.94%
controls:11.42%
cases:34.97%
controls:31.02%
78
732
235
2395
79
353
234
2774
11
55
302
3072
—
15
51
295
3067
37
343
249
2661
64
732
119
1628
Multidisciplinary treatment meeting
WZC20 [2001310890]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.28%
controls:0.42%
—
—
—
—
—
—
6
10
177
2350
Other and unspecified abdominal pain
R10.4 [45568113]
1.4e-01
9.6e-01
—
—
—
1.2e+00
8.2e-01
cases:6.39%
controls:5.60%
cases:3.19%
controls:1.25%
—
—
—
—
—
—
cases:5.24%
controls:1.56%
cases:12.57%
controls:5.93%
20
175
293
2952
10
39
303
3088
—
—
—
15
47
271
2957
23
140
160
2220
Abdominal CT examination both without and with contrast
JN3CD [2001305561]
2.1e+00
—
—
—
—
—
—
cases:2.24%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
306
3118
—
—
—
—
—
—
Erythrocytes [Presence] in Urine
33051-4 [3045424]
—
—
1.0e+50
—
—
2.0e+00
1.0e+00
—
—
—
—
cases:2.24%
controls:0.00%
—
—
—
—
cases:3.50%
controls:0.47%
cases:5.46%
controls:1.99%
—
—
7
0
306
3127
—
—
10
14
276
2990
10
47
173
2313
Open wound of other parts of lower leg
S81.8 [45564809]
2.0e+00
—
—
—
—
—
—
cases:1.92%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
307
3119
—
—
—
—
—
—
High dependency care
WX882 [2001310847]
2.0e+00
—
—
—
—
—
—
cases:1.92%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
307
3119
—
—
—
—
—
—
Sepsis due to other Gram-negative organisms
A41.5 [45556902]
2.0e+00
—
—
—
—
—
—
cases:2.56%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
8
11
305
3116
—
—
—
—
—
—
Abdominal aortic aneurysm, without mention of rupture
I71.4 [45572130]
1.2e+00
2.0e+00
—
—
—
1.8e+00
—
cases:2.24%
controls:0.67%
cases:2.56%
controls:0.35%
—
—
—
—
—
—
cases:2.10%
controls:0.37%
—
—
7
21
306
3106
8
11
305
3116
—
—
—
6
11
280
2993
—
Parathyrin.intact [Moles/volume] in Serum or Plasma
14866-8 [3010566]
-1.0e+50
—
—
—
—
—
2.0e+00
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
cases:3.28%
controls:0.47%
0
7
313
3120
—
—
—
—
—
6
11
177
2349
Other chronic renal failure
N18.8 [45534123]
1.4e+00
1.9e+00
—
—
—
2.0e+00
—
cases:1.60%
controls:0.42%
cases:1.92%
controls:0.29%
—
—
—
—
—
—
cases:2.80%
controls:0.40%
—
—
5
13
308
3114
6
9
307
3118
—
—
—
8
12
278
2992
—
Counselling and guidance which enhance independent living
R2130 [2001310196]
—
—
—
—
—
1.9e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:3.15%
controls:0.47%
cases:3.83%
controls:1.19%
—
—
—
—
—
9
14
277
2990
7
28
176
2332
Cancer Ag 19-9 [Units/volume] in Serum or Plasma
24108-3 [3022914]
1.8e+00
—
—
—
—
—
1.9e+00
cases:1.92%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:3.83%
controls:0.59%
6
10
307
3117
—
—
—
—
—
7
14
176
2346
Back syndrome with radiating pain
L86 [2002000705]
—
—
—
—
—
-1.0e+50
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:3.83%
controls:0.59%
—
—
—
—
—
0
6
286
2998
7
14
176
2346
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
1.0e+00
1.9e+00
-1.0e+50
—
1.0e+50
1.4e+00
2.3e-01
cases:2.24%
controls:0.80%
cases:3.19%
controls:0.51%
cases:0.00%
controls:0.16%
—
—
cases:2.58%
controls:0.00%
cases:2.80%
controls:0.70%
cases:3.28%
controls:2.63%
7
25
306
3102
10
16
303
3111
0
5
313
3122
—
8
0
302
3118
8
21
278
2983
6
62
177
2298
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.92%
controls:0.81%
—
—
—
—
—
—
9
19
174
2341
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
7.3e-01
—
—
—
—
1.4e+00
1.8e+00
cases:2.24%
controls:1.09%
—
—
—
—
—
—
—
—
cases:2.10%
controls:0.53%
cases:7.65%
controls:1.31%
7
34
306
3093
—
—
—
—
6
16
280
2988
14
31
169
2329
Urination problems other
U05 [2002001140]
1.8e+00
—
—
—
—
—
1.2e+00
cases:3.19%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:3.83%
controls:1.23%
10
17
303
3110
—
—
—
—
—
7
29
176
2331
Anaemia, unspecified
D64.9 [45600610]
2.9e-01
1.7e+00
—
—
—
1.1e+00
4.8e-01
cases:1.92%
controls:1.44%
cases:2.88%
controls:0.51%
—
—
—
—
—
—
cases:3.15%
controls:1.03%
cases:4.92%
controls:3.09%
6
45
307
3082
9
16
304
3111
—
—
—
9
31
277
2973
9
73
174
2287
Supraglottic ventilation device
WX702 [2001310818]
1.7e+00
—
—
—
—
—
—
cases:2.88%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
9
16
304
3111
—
—
—
—
—
—
Disease/condition unspecnature/site
A99 [2002000232]
7.5e-01
1.1e+00
—
—
-1.0e+50
1.7e+00
6.3e-01
cases:2.88%
controls:1.38%
cases:1.60%
controls:0.54%
—
—
—
—
cases:0.00%
controls:0.19%
cases:2.80%
controls:0.50%
cases:4.92%
controls:2.67%
9
43
304
3084
5
17
308
3110
—
—
0
6
310
3112
8
15
278
2989
9
63
174
2297
Transurethral resection of prostate
KED22 [2001306138]
6.8e-01
—
—
—
—
2.0e+00
1.7e+00
cases:2.56%
controls:1.31%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.23%
cases:4.92%
controls:0.93%
8
41
305
3086
—
—
—
—
5
7
281
2997
9
22
174
2338
Gas panel - Capillary blood
24337-8 [3022313]
8.7e-01
—
—
—
—
1.7e+00
9.5e-01
cases:2.56%
controls:1.09%
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.80%
cases:4.37%
controls:1.74%
8
34
305
3093
—
—
—
—
12
24
274
2980
8
41
175
2319
Retention of urine
R33 [45587507]
8.4e-01
1.7e+00
—
—
—
9.8e-01
7.5e-01
cases:3.83%
controls:1.69%
cases:3.83%
controls:0.74%
—
—
—
—
—
—
cases:2.45%
controls:0.93%
cases:6.01%
controls:2.92%
12
53
301
3074
12
23
301
3104
—
—
—
7
28
279
2976
11
69
172
2291
Differential panel, method unspecified - Blood
69738-3 [42870588]
2.5e-01
6.0e-01
1.1e+00
—
7.4e-01
9.3e-01
7.3e-01
cases:9.58%
controls:7.61%
cases:7.35%
controls:4.16%
cases:2.24%
controls:0.74%
—
—
cases:1.94%
controls:0.93%
cases:9.79%
controls:4.09%
cases:20.77%
controls:11.19%
30
238
283
2889
23
130
290
2997
7
23
306
3104
—
6
29
304
3089
28
123
258
2881
38
264
145
2096
Bacterial infection, unspecified
A49.9 [45590816]
5.6e-01
—
—
—
—
1.6e+00
1.1e+00
cases:2.56%
controls:1.47%
—
—
—
—
—
—
—
—
cases:3.50%
controls:0.70%
cases:5.46%
controls:1.95%
8
46
305
3081
—
—
—
—
10
21
276
2983
10
46
173
2314
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
1.4e-01
3.1e-01
1.2e+00
—
1.6e+00
6.5e-01
2.0e-01
cases:14.38%
controls:12.70%
cases:8.63%
controls:6.46%
cases:2.56%
controls:0.80%
—
—
cases:2.58%
controls:0.51%
cases:11.19%
controls:6.16%
cases:21.31%
controls:18.14%
45
397
268
2730
27
202
286
2925
8
25
305
3102
—
8
16
302
3102
32
185
254
2819
39
428
144
1932
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
5.1e-01
1.2e+00
—
—
—
1.3e+00
1.6e+00
cases:3.51%
controls:2.14%
cases:3.51%
controls:1.06%
—
—
—
—
—
—
cases:3.50%
controls:0.97%
cases:12.57%
controls:2.80%
11
67
302
3060
11
33
302
3094
—
—
—
10
29
276
2975
23
66
160
2294
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
8.7e-01
1.2e+00
—
—
—
1.8e+00
1.6e+00
cases:2.56%
controls:1.09%
cases:1.60%
controls:0.48%
—
—
—
—
—
—
cases:1.75%
controls:0.30%
cases:6.01%
controls:1.27%
8
34
305
3093
5
15
308
3112
—
—
—
5
9
281
2995
11
30
172
2330
Flexible bronchoscopy
UGC12 [2001303610]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.37%
controls:0.93%
—
—
—
—
—
—
8
22
175
2338
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
1.8e-01
—
—
—
—
—
1.6e+00
cases:1.60%
controls:1.34%
—
—
—
—
—
—
—
—
—
—
cases:4.92%
controls:1.06%
5
42
308
3085
—
—
—
—
—
9
25
174
2335
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
4.4e-01
7.3e-01
—
—
—
8.4e-01
4.7e-01
cases:12.78%
controls:8.63%
cases:9.58%
controls:4.86%
—
—
—
—
—
—
cases:10.49%
controls:4.83%
cases:24.04%
controls:16.48%
40
270
273
2857
30
152
283
2975
—
—
—
30
145
256
2859
44
389
139
1971
Leukocytes [Presence] in Urine
33052-2 [3045414]
2.0e+00
1.7e+00
—
—
—
1.6e+00
7.2e-01
cases:1.60%
controls:0.22%
cases:2.24%
controls:0.42%
—
—
—
—
—
—
cases:4.55%
controls:1.00%
cases:9.84%
controls:5.04%
5
7
308
3120
7
13
306
3114
—
—
—
13
30
273
2974
18
119
165
2241
pH of Urine by Test strip
5803-2 [3022621]
5.8e-01
1.5e+00
—
—
—
7.9e-01
5.9e-01
cases:3.19%
controls:1.82%
cases:3.51%
controls:0.77%
—
—
—
—
—
—
cases:1.75%
controls:0.80%
cases:7.10%
controls:4.07%
10
57
303
3070
11
24
302
3103
—
—
—
5
24
281
2980
13
96
170
2264
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
5.3e-01
6.4e-01
—
—
—
1.5e+00
4.6e-01
cases:5.43%
controls:3.26%
cases:2.88%
controls:1.54%
—
—
—
—
—
—
cases:3.50%
controls:0.77%
cases:4.37%
controls:2.80%
17
102
296
3025
9
48
304
3079
—
—
—
10
23
276
2981
8
66
175
2294
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
3.6e-01
1.5e+00
—
—
—
9.0e-01
5.6e-01
cases:1.92%
controls:1.34%
cases:3.51%
controls:0.80%
—
—
—
—
—
—
cases:3.15%
controls:1.30%
cases:4.92%
controls:2.88%
6
42
307
3085
11
25
302
3102
—
—
—
9
39
277
2965
9
68
174
2292
FEV1/FVC
19926-5 [3011505]
5.2e-01
9.7e-01
—
—
—
5.3e-01
1.5e+00
cases:5.43%
controls:3.29%
cases:2.24%
controls:0.86%
—
—
—
—
—
—
cases:1.75%
controls:1.03%
cases:7.10%
controls:1.69%
17
103
296
3024
7
27
306
3100
—
—
—
5
31
281
2973
13
40
170
2320
FEV1
20150-9 [3024653]
5.2e-01
9.7e-01
—
—
—
5.3e-01
1.5e+00
cases:5.43%
controls:3.29%
cases:2.24%
controls:0.86%
—
—
—
—
—
—
cases:1.75%
controls:1.03%
cases:7.10%
controls:1.69%
17
103
296
3024
7
27
306
3100
—
—
—
5
31
281
2973
13
40
170
2320
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
5.2e-01
9.7e-01
—
—
—
5.3e-01
1.5e+00
cases:5.43%
controls:3.29%
cases:2.24%
controls:0.86%
—
—
—
—
—
—
cases:1.75%
controls:1.03%
cases:7.10%
controls:1.69%
17
103
296
3024
7
27
306
3100
—
—
—
5
31
281
2973
13
40
170
2320
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
6.6e-01
—
—
—
—
1.5e+00
1.0e+00
cases:2.88%
controls:1.50%
—
—
—
—
—
—
—
—
cases:3.15%
controls:0.73%
cases:6.01%
controls:2.20%
9
47
304
3080
—
—
—
—
9
22
277
2982
11
52
172
2308
Gas panel - Arterial blood
24336-0 [3019060]
5.2e-01
—
-1.0e+50
1.0e+50
—
1.5e+00
—
cases:2.56%
controls:1.54%
—
—
cases:0.00%
controls:0.16%
cases:1.92%
controls:0.00%
—
—
cases:3.15%
controls:0.73%
—
—
8
48
305
3079
—
0
5
313
3122
6
0
307
3127
—
9
22
277
2982
—
FEV1 --post bronchodilation
20155-8 [3023550]
5.9e-01
8.3e-01
—
—
—
—
1.5e+00
cases:5.11%
controls:2.91%
cases:1.60%
controls:0.70%
—
—
—
—
—
—
—
—
cases:6.01%
controls:1.44%
16
91
297
3036
5
22
308
3105
—
—
—
—
11
34
172
2326
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
5.9e-01
8.3e-01
—
—
—
—
1.5e+00
cases:5.11%
controls:2.91%
cases:1.60%
controls:0.70%
—
—
—
—
—
—
—
—
cases:6.01%
controls:1.44%
16
91
297
3036
5
22
308
3105
—
—
—
—
11
34
172
2326
FEV1 percent change
69983-5 [42868472]
5.9e-01
8.3e-01
—
—
—
—
1.5e+00
cases:5.11%
controls:2.91%
cases:1.60%
controls:0.70%
—
—
—
—
—
—
—
—
cases:6.01%
controls:1.44%
16
91
297
3036
5
22
308
3105
—
—
—
—
11
34
172
2326
FEV1/FVC --post bronchodilation
69970-2 [42868459]
5.9e-01
8.3e-01
—
—
—
—
1.5e+00
cases:5.11%
controls:2.91%
cases:1.60%
controls:0.70%
—
—
—
—
—
—
—
—
cases:6.01%
controls:1.44%
16
91
297
3036
5
22
308
3105
—
—
—
—
11
34
172
2326
FVC percent change Respiratory system
69982-7 [42868471]
5.9e-01
8.3e-01
—
—
—
—
1.5e+00
cases:5.11%
controls:2.91%
cases:1.60%
controls:0.70%
—
—
—
—
—
—
—
—
cases:6.01%
controls:1.44%
16
91
297
3036
5
22
308
3105
—
—
—
—
11
34
172
2326
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
8.9e-01
1.5e+00
—
—
—
1.2e+00
5.0e-01
cases:3.19%
controls:1.34%
cases:3.51%
controls:0.83%
—
—
—
—
—
—
cases:3.50%
controls:1.13%
cases:7.10%
controls:4.45%
10
42
303
3085
11
26
302
3101
—
—
—
10
34
276
2970
13
105
170
2255
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
6.5e-01
—
—
—
—
—
1.5e+00
cases:2.24%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
cases:5.46%
controls:1.31%
7
37
306
3090
—
—
—
—
—
10
31
173
2329
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
5.4e-01
1.5e+00
—
—
—
1.2e+00
8.7e-02
cases:2.24%
controls:1.31%
cases:3.19%
controls:0.77%
—
—
—
—
—
—
cases:3.50%
controls:1.03%
cases:3.83%
controls:3.52%
7
41
306
3086
10
24
303
3103
—
—
—
10
31
276
2973
7
83
176
2277
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
4.7e-01
1.4e+00
—
—
—
8.6e-01
—
cases:4.79%
controls:3.04%
cases:3.51%
controls:0.86%
—
—
—
—
—
—
cases:2.80%
controls:1.20%
—
—
15
95
298
3032
11
27
302
3100
—
—
—
8
36
278
2968
—
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
-5.1e-02
1.4e+00
—
—
-1.0e+50
6.5e-01
2.5e-01
cases:1.92%
controls:2.01%
cases:3.51%
controls:0.86%
—
—
—
—
cases:0.00%
controls:0.16%
cases:2.45%
controls:1.30%
cases:6.01%
controls:4.75%
6
63
307
3064
11
27
302
3100
—
—
0
5
310
3113
7
39
279
2965
11
112
172
2248
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
4.1e-01
1.4e+00
—
—
—
9.0e-01
5.6e-01
cases:1.92%
controls:1.28%
cases:3.19%
controls:0.80%
—
—
—
—
—
—
cases:3.15%
controls:1.30%
cases:4.92%
controls:2.88%
6
40
307
3087
10
25
303
3102
—
—
—
9
39
277
2965
9
68
174
2292
calcium (different salts in combination); oral
A12AA20 [21600872]
3.3e-01
2.9e-01
3.1e-01
—
3.0e-01
6.3e-01
7.5e-01
cases:13.10%
controls:9.79%
cases:10.54%
controls:8.09%
cases:3.19%
controls:2.37%
—
—
cases:3.23%
controls:2.41%
cases:14.34%
controls:8.19%
cases:21.86%
controls:11.69%
41
306
272
2821
33
253
280
2874
10
74
303
3053
—
10
75
300
3043
41
246
245
2758
40
276
143
2084
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
3.8e-01
7.6e-01
—
—
1.5e+00
1.3e+00
5.1e-01
cases:3.83%
controls:2.65%
cases:3.83%
controls:1.82%
—
—
—
—
cases:1.61%
controls:0.35%
cases:5.94%
controls:1.63%
cases:10.38%
controls:6.53%
12
83
301
3044
12
57
301
3070
—
—
5
11
305
3107
17
49
269
2955
19
154
164
2206
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
5.7e-01
1.1e+00
—
—
—
9.0e-01
1.3e+00
cases:3.51%
controls:2.01%
cases:2.24%
controls:0.74%
—
—
—
—
—
—
cases:2.10%
controls:0.87%
cases:8.74%
controls:2.54%
11
63
302
3064
7
23
306
3104
—
—
—
6
26
280
2978
16
60
167
2300
pH of Specimen
17433-4 [3019225]
8.3e-01
1.3e+00
—
—
—
9.7e-01
3.5e-01
cases:6.39%
controls:2.88%
cases:3.83%
controls:1.09%
—
—
—
—
—
—
cases:4.20%
controls:1.63%
cases:4.92%
controls:3.52%
20
90
293
3037
12
34
301
3093
—
—
—
12
49
274
2955
9
83
174
2277
metronidazole; oral, rectal
P01AB01 [21604857]
6.4e-01
1.3e+00
—
—
—
7.3e-01
1.7e-01
cases:9.27%
controls:5.12%
cases:3.83%
controls:1.09%
—
—
—
—
—
—
cases:2.45%
controls:1.20%
cases:6.01%
controls:5.13%
29
160
284
2967
12
34
301
3093
—
—
—
7
36
279
2968
11
121
172
2239
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.8e-01
7.4e-01
—
—
1.4e+00
1.3e+00
4.6e-01
cases:4.15%
controls:3.49%
cases:4.47%
controls:2.17%
—
—
—
—
cases:1.61%
controls:0.42%
cases:6.29%
controls:1.83%
cases:10.93%
controls:7.16%
13
109
300
3018
14
68
299
3059
—
—
5
13
305
3105
18
55
268
2949
20
169
163
2191
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
5.2e-02
3.8e-01
—
—
1.3e+00
-3.3e-02
-2.5e-01
cases:27.48%
controls:26.45%
cases:15.02%
controls:10.78%
—
—
—
—
cases:5.48%
controls:1.60%
cases:9.79%
controls:10.09%
cases:17.49%
controls:21.40%
86
827
227
2300
47
337
266
2790
—
—
17
50
293
3068
28
303
258
2701
32
505
151
1855
ibuprofen
R02AX02 [1588667]
5.2e-02
3.8e-01
—
—
1.3e+00
-3.3e-02
-2.5e-01
cases:27.48%
controls:26.45%
cases:15.02%
controls:10.78%
—
—
—
—
cases:5.48%
controls:1.60%
cases:9.79%
controls:10.09%
cases:17.49%
controls:21.40%
86
827
227
2300
47
337
266
2790
—
—
17
50
293
3068
28
303
258
2701
32
505
151
1855
Sedation and analgesia
WX002 [2001310758]
-1.6e-02
7.9e-01
—
—
—
5.0e-01
1.2e+00
cases:4.47%
controls:4.54%
cases:2.24%
controls:1.02%
—
—
—
—
—
—
cases:1.75%
controls:1.07%
cases:7.10%
controls:2.16%
14
142
299
2985
7
32
306
3095
—
—
—
5
32
281
2972
13
51
170
2309
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3.1e-01
7.0e-01
—
—
1.5e+00
1.2e+00
5.3e-01
cases:3.83%
controls:2.85%
cases:3.83%
controls:1.95%
—
—
—
—
cases:1.61%
controls:0.35%
cases:5.94%
controls:1.80%
cases:11.48%
controls:7.08%
12
89
301
3038
12
61
301
3066
—
—
5
11
305
3107
17
54
269
2950
21
167
162
2193
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
4.3e-01
7.0e-01
—
1.0e+50
—
1.2e+00
8.8e-01
cases:4.47%
controls:2.94%
cases:3.83%
controls:1.95%
—
—
cases:1.60%
controls:0.00%
—
—
cases:6.29%
controls:1.93%
cases:9.29%
controls:4.07%
14
92
299
3035
12
61
301
3066
—
5
0
308
3127
—
18
58
268
2946
17
96
166
2264
Actinic keratosis
L57.0 [45591640]
1.2e+00
—
—
—
—
6.4e-01
1.2e+00
cases:4.79%
controls:1.47%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.93%
cases:5.46%
controls:1.78%
15
46
298
3081
—
—
—
—
5
28
281
2976
10
42
173
2318
solifenacin; oral
G04BD08 [21602641]
1.2e+00
—
-1.0e+50
—
—
—
8.1e-01
cases:4.15%
controls:1.28%
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
cases:3.28%
controls:1.48%
13
40
300
3087
—
0
8
313
3119
—
—
—
6
35
177
2325
hypromellose
S01KA02 [21605115]
4.8e-01
8.1e-01
—
—
—
5.0e-01
1.2e+00
cases:4.15%
controls:2.62%
cases:2.56%
controls:1.15%
—
—
—
—
—
—
cases:1.75%
controls:1.07%
cases:7.65%
controls:2.50%
13
82
300
3045
8
36
305
3091
—
—
—
5
32
281
2972
14
59
169
2301
Fever, unspecified
R50.9 [45582716]
4.8e-01
1.2e+00
—
—
—
1.4e+00
1.1e+00
cases:2.88%
controls:1.79%
cases:1.60%
controls:0.48%
—
—
—
—
—
—
cases:3.15%
controls:0.77%
cases:7.10%
controls:2.42%
9
56
304
3071
5
15
308
3112
—
—
—
9
23
277
2981
13
57
170
2303
Application of soft bandage
SPAT1211 [2001700312]
1.1e+00
—
—
—
—
1.3e+00
—
cases:4.15%
controls:1.41%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.47%
—
—
13
44
300
3083
—
—
—
—
5
14
281
2990
—
Left side
ZXA05 [2001311347]
2.1e-01
—
—
1.0e+50
—
1.2e+00
1.1e+00
cases:6.07%
controls:4.96%
—
—
—
—
cases:1.60%
controls:0.00%
—
—
cases:3.50%
controls:1.07%
cases:7.65%
controls:2.67%
19
155
294
2972
—
—
5
0
308
3127
—
10
32
276
2972
14
63
169
2297
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
6.4e-01
7.8e-01
-1.0e+50
—
—
8.0e-01
1.1e+00
cases:9.90%
controls:5.47%
cases:4.47%
controls:2.11%
cases:0.00%
controls:0.45%
—
—
—
—
cases:4.55%
controls:2.10%
cases:14.21%
controls:5.30%
31
171
282
2956
14
66
299
3061
0
14
313
3113
—
—
13
63
273
2941
26
125
157
2235
Shortness of breath/dyspnoea
R02 [2002000883]
-3.7e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:1.92%
controls:2.75%
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
cases:7.10%
controls:2.54%
6
86
307
3041
0
23
313
3104
—
—
—
—
13
60
170
2300
Other specified counselling
Z71.8 [45581061]
4.1e-01
5.0e-01
—
—
1.5e+00
1.1e+00
-3.8e-02
cases:5.75%
controls:3.90%
cases:5.11%
controls:3.17%
—
—
—
—
cases:1.94%
controls:0.42%
cases:6.64%
controls:2.40%
cases:9.29%
controls:9.62%
18
122
295
3005
16
99
297
3028
—
—
6
13
304
3105
19
72
267
2932
17
227
166
2133
Vascular Surgery
77 [38004496]
5.6e-01
1.0e+00
—
—
—
3.5e-01
4.2e-01
cases:7.67%
controls:4.54%
cases:4.79%
controls:1.79%
—
—
—
—
—
—
cases:3.15%
controls:2.23%
cases:8.20%
controls:5.55%
24
142
289
2985
15
56
298
3071
—
—
—
9
67
277
2937
15
131
168
2229
mirabegron; oral
G04BD12 [43534790]
7.5e-01
5.7e-01
—
—
—
1.0e+00
5.4e-01
cases:6.71%
controls:3.29%
cases:4.15%
controls:2.40%
—
—
—
—
—
—
cases:6.64%
controls:2.53%
cases:8.20%
controls:4.96%
21
103
292
3024
13
75
300
3052
—
—
—
19
76
267
2928
15
117
168
2243
Supine thorax X-ray examination
GD1QA [2001303648]
1.1e-01
5.6e-01
-1.0e+50
—
—
8.5e-01
9.6e-01
cases:3.19%
controls:2.88%
cases:2.88%
controls:1.66%
cases:0.00%
controls:0.19%
—
—
—
—
cases:4.20%
controls:1.83%
cases:14.75%
controls:6.23%
10
90
303
3037
9
52
304
3075
0
6
313
3121
—
—
12
55
274
2949
27
147
156
2213
pivmecillinam; oral
J01CA08 [21602827]
1.6e-01
9.4e-01
1.7e+00
—
—
7.7e-01
4.9e-01
cases:7.03%
controls:6.04%
cases:5.75%
controls:2.33%
cases:1.60%
controls:0.29%
—
—
—
—
cases:5.24%
controls:2.50%
cases:9.84%
controls:6.27%
22
189
291
2938
18
73
295
3054
5
9
308
3118
—
—
15
75
271
2929
18
148
165
2212
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
8.9e-02
7.8e-01
—
—
1.5e+00
9.2e-01
3.1e-01
cases:6.71%
controls:6.17%
cases:7.35%
controls:3.52%
—
—
—
—
cases:1.61%
controls:0.35%
cases:8.04%
controls:3.36%
cases:14.75%
controls:11.23%
21
193
292
2934
23
110
290
3017
—
—
5
11
305
3107
23
101
263
2903
27
265
156
2095
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2.2e-01
4.6e-01
—
—
1.4e+00
9.2e-01
1.4e-01
cases:10.86%
controls:8.89%
cases:8.95%
controls:5.82%
—
—
—
—
cases:2.58%
controls:0.67%
cases:11.54%
controls:4.96%
cases:19.67%
controls:17.54%
34
278
279
2849
28
182
285
2945
—
—
8
21
302
3097
33
149
253
2855
36
414
147
1946
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
9.1e-01
—
-1.0e+50
—
—
—
3.9e-01
cases:6.39%
controls:2.69%
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
cases:3.28%
controls:2.25%
20
84
293
3043
—
0
5
313
3122
—
—
—
6
53
177
2307
Extraction of tooth
EBA00 [2001301923]
2.4e-01
9.1e-01
-1.0e+50
—
—
9.0e-02
-5.4e-01
cases:10.22%
controls:8.22%
cases:6.39%
controls:2.69%
cases:0.00%
controls:0.29%
—
—
—
—
cases:2.80%
controls:2.56%
cases:6.01%
controls:9.92%
32
257
281
2870
20
84
293
3043
0
9
313
3118
—
—
8
77
278
2927
11
234
172
2126
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
2.5e-01
9.1e-01
—
—
—
8.3e-01
8.8e-01
cases:9.58%
controls:7.64%
cases:4.79%
controls:1.98%
—
—
—
—
—
—
cases:4.90%
controls:2.20%
cases:15.30%
controls:6.95%
30
239
283
2888
15
62
298
3065
—
—
—
14
66
272
2938
28
164
155
2196
Handing over of treatment supplies
SPAT1262 [2001700363]
2.3e-01
5.8e-01
—
—
—
7.3e-01
8.1e-01
cases:8.63%
controls:6.97%
cases:5.75%
controls:3.29%
—
—
—
—
—
—
cases:6.64%
controls:3.33%
cases:14.21%
controls:6.86%
27
218
286
2909
18
103
295
3024
—
—
—
19
100
267
2904
26
162
157
2198
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
2.9e-01
6.5e-01
1.1e+00
1.0e+50
1.4e+00
7.7e-01
-1.3e-01
cases:13.42%
controls:10.36%
cases:9.27%
controls:5.08%
cases:2.88%
controls:0.99%
cases:4.79%
controls:0.00%
cases:2.90%
controls:0.74%
cases:11.19%
controls:5.53%
cases:12.02%
controls:13.43%
42
324
271
2803
29
159
284
2968
9
31
304
3096
15
0
298
3127
9
23
301
3095
32
166
254
2838
22
317
161
2043
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
3.4e-01
7.3e-01
—
—
—
5.7e-01
3.9e-01
cases:17.25%
controls:12.95%
cases:13.10%
controls:6.75%
—
—
—
—
—
—
cases:11.19%
controls:6.66%
cases:29.51%
controls:22.08%
54
405
259
2722
41
211
272
2916
—
—
—
32
200
254
2804
54
521
129
1839
Pulmonary Disease
29 [38004472]
1.6e-01
-1.2e-01
4.8e-01
—
—
3.6e-01
7.3e-01
cases:14.70%
controls:12.86%
cases:5.75%
controls:6.46%
cases:1.60%
controls:0.99%
—
—
—
—
cases:8.74%
controls:6.26%
cases:22.95%
controls:12.54%
46
402
267
2725
18
202
295
2925
5
31
308
3096
—
—
25
188
261
2816
42
296
141
2064
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
1.5e-01
5.2e-01
—
—
8.1e-01
7.2e-01
2.6e-01
cases:17.57%
controls:15.51%
cases:13.10%
controls:8.25%
—
—
—
—
cases:1.94%
controls:0.87%
cases:13.64%
controls:7.12%
cases:24.59%
controls:20.13%
55
485
258
2642
41
258
272
2869
—
—
6
27
304
3091
39
214
247
2790
45
475
138
1885

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
207
108
53.99
291.93
7.2
1.8
—
—
—
0
0
125
187
10.42
86.93
2.3
1.1
—
—
—
0
0
71
63
14.26
70.72
1.5
1.3
—
—
—
0
0
224
829
6.89
59.84
7.7
3.4
—
—
—
0
0
194
681
5.81
53.46
4.0
1.7
—
—
—
0
0
203
936
4.29
34.85
11.2
3.3
287.84
147.04
e6/l
0.50
178
716
165
661
4.14
34.58
6.8
2.4
4.38
4.30
e6/l
0.04
156
595
220
1115
4.23
32.01
4.4
2.5
—
—
estimate
—
0
0
179
802
3.85
30.98
11.0
3.1
0.38
0.36
e6/l
0.04
162
584
203
1017
3.80
29.04
12.4
3.9
247.41
109.70
e6/l
0.57
180
733
177
836
3.55
27.26
6.9
4.2
—
—
—
0
0
64
147
5.21
27.19
4.4
1.3
52.69
2.81
ug/l
0.99
56
113
137
553
3.61
27.02
7.4
2.8
536.24
532.51
mosm/kgh2o
0.09
127
474
168
784
3.45
26.07
3.6
2.2
—
—
—
0
0
268
1686
4.95
26.03
15.6
4.9
4.80
2617.24
e6/l
—
5
34
226
1287
3.68
24.97
10.5
3.9
9.41
12.81
umol/l
12.43
220
1216
86
276
3.91
23.53
9.3
7.0
12.08
11.34
mmol/l
0.34
79
261
222
1332
3.26
20.81
13.8
5.4
4.65
4.49
e9/l
0.40
191
1134
205
1199
3.03
19.66
7.8
4.0
32.63
35.04
g/l
6.94
197
1118
227
1429
3.11
18.59
23.8
18.4
1.28
1.37
inr
1.79
204
1209
110
475
3.02
18.19
11.1
3.1
1.13
1.27
e6/l
0.15
82
233
224
1419
3.00
17.76
10.9
6.2
1.20
1.21
mmol/l
0.56
192
1210
112
515
2.82
16.22
10.6
2.9
1.61
1.03
e6/l
1.08
81
275
72
276
3.09
14.34
11.2
8.3
—
—
—
0
0
234
1619
2.73
13.89
8.4
5.0
7.00
6.89
mmol/l
0.43
228
1544
199
1276
2.52
13.86
10.2
5.9
1.20
1.20
mmol/l
0.45
183
1150
183
1130
2.48
13.83
6.4
5.1
9.08
9.14
%
0.08
177
1032
183
1139
2.45
13.47
6.5
5.2
22.14
25.47
%
3.21
178
1060
181
1128
2.42
13.18
6.4
5.0
2.52
2.98
%
1.96
173
1035
88
398
2.68
12.77
7.4
6.8
7.39
7.41
ph
1.32
37
245
87
395
2.66
12.50
7.4
6.8
13.47
11.27
kpa
3.68
81
386
87
395
2.66
12.50
7.5
6.8
5.19
5.08
kpa
0.59
82
386
203
1352
2.41
12.42
7.0
4.1
0.00
0.00
estimate
-0.00
54
279
257
1913
2.87
12.33
13.4
5.5
86.73
79.45
u/l
1.99
251
1769
86
392
2.64
12.24
7.4
6.8
-0.88
1.16
mmol/l
3.47
67
324
61
233
3.01
12.10
3.9
1.9
0.00
0.00
estimate
—
10
44
142
826
2.31
11.74
6.6
3.4
7.38
7.40
ph
2.27
112
580
203
1374
2.34
11.65
7.2
4.1
23.79
0.00
estimate
0.49
56
288
116
626
2.35
11.35
7.0
3.8
84.01
83.01
%
0.16
116
618
51
182
3.15
11.34
1.8
1.4
—
—
—
0
0
203
1384
2.31
11.30
7.2
4.1
0.00
0.01
estimate
0.50
54
267
38
114
3.65
11.08
3.6
1.8
0.00
0.00
estimate
—
6
33
186
1246
2.20
10.50
6.3
5.0
0.68
0.62
e9/l
1.83
157
1042
186
1252
2.19
10.30
6.2
5.0
0.04
0.04
e9/l
0.28
159
1052
138
828
2.19
10.23
4.4
2.2
54.17
65.04
u/l
1.06
132
759
87
433
2.39
10.07
3.6
2.8
19.45
22.64
%
1.35
80
400
136
820
2.16
9.88
6.3
5.0
—
—
—
0
0
186
1268
2.14
9.76
6.4
5.1
1.86
1.75
e9/l
0.26
158
1093
61
263
2.64
9.53
5.4
2.4
0.29
0.43
e6/l
0.77
61
248
188
1295
2.12
9.50
6.3
5.0
0.19
0.21
e9/l
0.91
160
1102
166
1092
2.10
9.48
5.8
3.7
6.19
6.27
ph
0.42
84
603
68
314
2.49
9.20
2.0
1.8
—
—
—
0
0
89
466
2.27
9.06
3.4
2.7
2.12
2.19
g/l
0.49
82
429
94
509
2.21
8.78
3.4
2.7
10.35
12.42
umol/l
2.15
88
472
90
485
2.20
8.47
2.5
1.9
29.44
29.93
s
0.42
90
468
51
213
2.66
8.45
6.6
4.0
7.40
7.41
ph
0.72
46
178
128
792
2.04
8.36
2.4
2.3
2.81
2.85
mg/l
0.07
112
671
138
898
1.96
7.65
5.4
2.1
2.33
2.35
mmol/l
0.58
128
776
15
19
8.23
7.19
1.1
1.7
19.32
24.19
ng/l
0.56
15
19
28
92
3.24
7.08
2.6
2.3
354.69
258.84
mg/l
0.32
13
31
14
17
8.56
6.90
1.1
1.1
—
—
—
0
0
28
97
3.07
6.50
1.5
1.4
—
—
—
0
0
68
362
2.12
6.45
6.8
3.5
7.37
7.38
ph
0.85
45
214
9
5
18.47
6.30
1.0
1.0
—
—
—
0
0
36
147
2.64
6.21
7.6
4.3
—
—
—
0
0
157
1119
1.80
6.16
3.7
3.1
183.10
145.01
ug/l
1.09
143
1021
99
615
1.89
6.04
1.5
1.3
—
—
—
0
0
65
352
2.07
5.86
6.9
3.5
0.24
1.83
mmol/l
2.42
56
305
118
786
1.80
5.70
7.3
4.1
0.00
0.00
estimate
-0.00
46
253
276
2392
2.24
5.43
37.0
16.4
42.06
27.78
mg/l
7.17
266
1956
108
715
1.78
5.25
2.5
2.6
370.66
370.42
umol/l
0.01
90
605
106
698
1.78
5.24
6.7
3.7
0.09
0.00
estimate
0.49
33
217
41
194
2.28
5.16
4.6
3.1
1.14
0.61
%
0.42
22
46
93
594
1.80
5.07
4.0
2.1
2.50
2.44
mmol/l
3.72
82
515
50
260
2.10
4.99
1.4
1.3
—
—
—
0
0
95
615
1.78
4.94
5.0
4.5
64.42
401.10
ng/l
3.08
84
536
179
1382
1.68
4.86
2.6
2.3
86.88
94.00
pmol/l
1.41
112
728
68
402
1.88
4.72
2.4
2.1
1.82
1.72
%
0.30
57
358
36
172
2.23
4.44
1.9
1.4
—
—
—
0
0
41
208
2.12
4.36
4.6
3.3
1.15
0.72
%
0.42
20
49
55
311
1.93
4.35
2.5
2.4
74.05
65.80
e9/l
0.74
39
238
47
256
1.98
4.13
6.0
3.5
7.39
7.35
ph
0.98
36
168
18
63
2.97
4.13
4.2
4.0
—
—
—
0
0
12
26
4.75
4.10
3.4
2.1
-0.26
1.60
mmol/l
0.85
12
26
46
251
1.98
4.03
5.4
1.8
407.80
379.69
nmol/l
0.28
46
229
39
201
2.07
3.99
4.7
3.3
0.06
0.07
%
0.09
18
42
149
1136
1.59
3.97
2.4
2.5
80.32
78.88
nmol/l
0.22
132
979
11
23
4.92
3.90
1.2
1.7
—
—
—
0
0
178
1422
1.58
3.84
3.5
3.1
71.38
53.12
u/l
0.94
170
1300
76
493
1.71
3.83
4.7
4.0
—
—
—
0
0
40
214
2.00
3.70
8.0
3.2
1.21
1.22
mmol/l
0.23
35
173
42
234
1.92
3.47
6.8
4.1
160.55
103.81
ng/l
1.12
37
199
144
1120
1.53
3.35
20.5
10.7
0.00
0.00
e9/l
0.46
111
915
13
43
3.11
3.29
4.2
3.6
9.72
12.60
pmol/l
0.49
13
43
64
417
1.67
3.14
1.7
1.8
—
—
—
0
0
133
1031
1.50
3.07
7.6
4.3
0.03
0.01
estimate
0.19
37
225
36
203
1.87
2.88
5.1
3.5
0.00
0.00
%
-0.00
18
35
269
2438
1.71
2.87
32.6
15.6
—
—
—
0
0
97
713
1.52
2.85
9.8
4.0
—
—
—
0
0
76
1040
0.65
2.80
2.0
2.0
1.70
1.26
mmol/l
1.06
65
835
35
198
1.86
2.78
7.1
3.9
—
—
—
0
0
5
7
7.23
2.56
2.0
1.0
879.00
104.29
nmol/l
—
5
7
5
7
7.23
2.56
2.2
1.3
3043.00
213.86
e6/l
—
5
7
6
11
5.54
2.55
10.2
2.9
0.33
0.91
index
—
6
11
36
212
1.79
2.53
3.9
2.7
5.95
6.03
ph
0.29
30
162
17
76
2.31
2.49
8.8
3.1
1.60
1.35
index
—
10
37
38
229
1.75
2.47
1.9
1.4
—
—
—
0
0
279
2581
1.71
2.40
55.7
25.0
238.29
233.60
e9/l
0.50
274
2505
279
2581
1.71
2.40
55.6
25.0
4.17
4.45
e12/l
13.94
274
2490
279
2582
1.70
2.38
55.7
25.1
7.51
6.84
e9/l
4.54
274
2495
5
8
6.33
2.38
2.2
2.4
36.00
53.57
%
—
5
8
136
1109
1.40
2.22
2.7
3.4
2845.39
1841.91
ng/l
0.68
124
964
5
9
5.62
2.22
2.2
1.1
134.40
5.18
nmol/l
—
5
9
272
2518
1.59
2.11
18.4
10.8
25.11
25.23
u/l
0.04
266
2401
23
126
1.89
2.04
2.3
1.9
—
—
—
0
0
18
92
2.01
1.94
1.3
1.2
—
—
—
0
0
134
1110
1.36
1.92
4.4
4.3
15.20
8.48
mg/mmol
0.63
90
711
24
137
1.81
1.89
2.7
2.5
293.17
704.74
ug/l
0.66
24
130
12
53
2.31
1.83
1.1
1.2
—
—
—
0
0
20
111
1.86
1.73
2.5
1.4
11.08
11.06
g/l
0.01
20
97
33
213
1.61
1.71
2.7
1.5
—
—
—
0
0
244
2241
1.39
1.68
5.7
5.0
2.09
2.04
mu/l
0.13
224
1991
6
19
3.20
1.67
1.0
1.1
—
—
—
0
0
30
192
1.62
1.61
4.2
2.8
0.66
0.62
%
0.22
30
192
129
1085
1.32
1.61
3.5
3.6
83.76
48.36
mg/l
0.81
90
717
10
44
2.31
1.57
1.6
2.0
33.80
32.77
pg
—
10
44
33
218
1.57
1.56
4.5
4.1
—
—
—
0
0
130
1098
1.31
1.56
3.5
3.5
6.51
7.60
mmol/l
2.78
104
916
8
33
2.46
1.55
1.1
1.0
—
—
—
0
0
25
155
1.67
1.52
2.5
1.8
1.60
1.58
g/l
0.05
18
135
30
197
1.58
1.47
4.1
2.8
1.52
1.06
%
0.60
30
197
78
623
1.33
1.37
1.8
1.9
1012.75
1194.74
nmol/l
1.09
55
475
8
36
2.25
1.25
1.3
1.7
9.64
10.35
%
—
8
36
6
25
2.43
1.25
1.5
1.4
—
—
—
0
0
163
1448
1.26
1.24
5.3
4.6
2.34
2.13
ug/l
0.22
139
1286
116
994
1.26
1.19
1.9
1.8
18.90
20.19
nmol/l
0.41
101
833
23
153
1.54
1.10
7.9
3.6
1.02
1.02
ratio
0.24
23
142
197
1812
1.23
1.01
4.2
3.8
15.15
15.10
pmol/l
0.08
176
1600
31
417
0.72
0.98
1.2
1.3
31.28
38.69
iu/ml
—
5
123
7
36
1.97
0.97
1.3
1.3
—
—
—
0
0
7
36
1.97
0.97
1.3
1.3
—
—
—
0
0
7
36
1.97
0.97
1.3
1.3
—
—
—
0
0
7
36
1.97
0.97
1.3
1.3
—
—
—
0
0
6
27
2.25
0.94
1.0
1.0
—
—
—
0
0
15
94
1.63
0.92
5.9
1.3
3.32
1.49
ratio
—
9
54
29
389
0.72
0.91
1.2
1.3
3.14
10.74
u/ml
—
8
121
134
1202
1.20
0.84
4.9
4.4
48.92
75.94
ng/l
0.46
118
960
6
32
1.89
0.82
3.2
1.7
16.70
16.74
%
—
6
32
6
32
1.89
0.82
1.3
1.8
6.67
8.41
mmol/l
—
6
32
0
26
0.00
0.79
0.0
1.3
—
0.65
—
0
8
12
77
1.58
0.69
9.2
4.2
—
—
—
0
0
7
44
1.60
0.65
2.0
2.5
9.29
11.09
mmol/l
—
7
44
80
703
1.18
0.62
1.9
1.9
364.39
26352949.16
pmol/l
0.78
62
573
0
20
0.00
0.60
0.0
1.1
—
0.37
—
0
12
0
20
0.00
0.60
0.0
1.1
—
2.75
—
0
12
8
53
1.52
0.59
1.4
1.4
29.88
25.93
g/l
—
8
46
6
35
1.73
0.58
1.2
1.2
—
—
—
0
0
5
87
0.57
0.57
1.0
1.4
1.00
1.07
g/l
—
5
82
6
36
1.68
0.57
1.8
2.1
89.53
90.68
%
—
6
36
6
36
1.68
0.57
1.5
1.4
32197.17
71548.05
e6/l
—
6
19
6
37
1.63
0.56
1.2
1.2
—
—
—
0
0
42
352
1.22
0.54
1.4
1.2
—
—
—
0
0
66
748
0.85
0.53
4.1
3.9
—
—
—
0
0
10
66
1.53
0.53
4.3
4.2
21.90
27.39
mg/l
—
5
55
6
100
0.59
0.52
1.0
1.2
—
0.23
—
0
8
7
45
1.57
0.49
1.4
1.4
796.71
2247.30
e6/l
—
7
30
7
45
1.57
0.49
2.9
2.4
1.20
1.19
mmol/l
—
7
45
7
45
1.57
0.49
1.0
1.2
—
—
nmol/l
—
0
0
7
47
1.50
0.48
2.9
2.4
108.57
105.43
mmol/l
—
7
47
7
47
1.50
0.48
2.9
2.4
4.10
4.09
mmol/l
—
7
47
74
662
1.15
0.47
8.4
4.4
1.02
1.02
kg/l
0.06
63
449
7
51
1.38
0.44
1.1
1.1
—
—
—
0
0
14
104
1.36
0.44
1.9
1.3
—
—
—
0
0
36
305
1.20
0.43
1.4
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
48
421
1.17
0.40
1.2
1.3
2.41
2.93
g/l
1.21
32
248
0
19
0.00
0.39
0.0
1.1
—
0.31
—
0
11
6
42
1.44
0.35
1.3
1.1
—
—
—
0
0
6
43
1.40
0.35
1.3
1.8
—
120.01
—
0
20
11
83
1.34
0.32
4.9
3.6
0.74
0.83
nmol/l
0.32
11
67
88
818
1.11
0.31
2.5
3.1
0.65
0.77
ug/l
0.91
63
576
7
53
1.33
0.31
1.1
2.8
—
—
—
0
0
7
56
1.26
0.29
1.1
1.4
—
—
—
0
0
247
2413
1.11
0.29
6.3
5.9
6.21
6.18
mmol/l
0.16
221
2159
58
529
1.12
0.29
1.5
1.7
2.50
1.52
mg/l
0.76
47
414
10
77
1.31
0.26
1.2
1.3
—
—
—
0
0
13
159
0.81
0.25
1.1
1.3
—
—
—
0
0
231
2259
1.08
0.23
4.5
4.8
1.29
1.25
mmol/l
0.48
203
2023
0
12
0.00
0.21
0.0
1.1
—
1.26
—
0
5
0
13
0.00
0.21
0.0
1.1
—
2.87
—
0
6
13
108
1.21
0.20
1.2
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
224.44
—
0
9
6
50
1.20
0.20
1.0
1.2
—
—
—
0
0
6
53
1.13
0.19
1.2
1.1
—
—
—
0
0
5
67
0.74
0.17
1.0
1.2
—
—
—
0
0
241
2374
1.06
0.15
8.6
7.7
41.37
40.77
mmol/mol
0.54
220
2189
12
102
1.18
0.15
3.0
2.7
3.64
4.29
pmol/l
1.33
12
90
30
326
0.91
0.14
1.1
1.3
432.00
504.69
titre
—
5
81
51
483
1.07
0.13
1.2
1.3
0.89
1.67
u/ml
0.89
12
136
18
162
1.12
0.12
1.3
1.2
—
—
—
0
0
246
2436
1.04
0.09
6.1
6.8
2.31
2.43
mmol/l
1.50
225
2216
14
155
0.90
0.09
2.4
2.6
—
12.27
—
0
7
12
134
0.89
0.09
1.3
1.4
—
35.25
—
0
12
20
186
1.08
0.07
1.4
1.6
—
—
—
0
0
237
2384
0.98
0.04
5.3
5.8
4.10
4.28
mmol/l
1.96
214
2179
10
94
1.07
0.01
4.0
3.0
1.53
1.63
mmol/l
—
10
89
16
154
1.04
0.00
2.6
2.5
—
—
—
0
0
236
2366
0.99
0.00
5.2
5.7
1.33
1.41
mmol/l
2.31
216
2137
14
136
1.03
0.00
1.1
1.2
235.19
351.15
u/ml
0.27
14
125
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
1.17
—
0
5
0
8
0.00
-0.00
0.0
1.3
—
12.34
—
0
8
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.03
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
-0.00
5.8
2.1
57.20
60.39
%
—
5
49
0
5
0.00
-0.00
0.0
1.0
—
13.54
—
0
5
6
63
0.95
-0.00
1.3
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
6
64
0.94
-0.00
1.5
1.9
19.48
12.26
mg/l
—
6
59

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_URETER_WIDE – Malignant neoplasm of ureter, including Hilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).